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Low density lipoprotein (LDL) particle size heterogeneity and oxidizability have 
been recognized as risk factors for coronary artery disease. This study examined these 
and other lipid, lipoprotein and apolipoprotein atherogenic properties in three groups of 
patients : non-insulin dependent diabetic millitus (NIDDM), hypertriglyceridaemia, and 
coronary artery disease (CAD). The effect of hypolipidaemic drugs (lovastatin, 
acipimox and bezafibrate) on the quantitative changes of lipid-lipoprotein-
apolipoprotein profile and qualitative changes of LDL particles size and oxidizability 
were also studied. 
Compared to the sex- and age-matched controls, NIDDM and CAD patients 
had significant shorter LDL oxidation lag time ( 62.2 vs 75.5 min, p <0.0001 and 73.9 
vs 79.3 min, p <0.05 respectively), whereas hypertriglyceridaemic patients only 
demonstrated a non-significant shorter lag time ( 68.7 vs 75.4 min, NS). The oxidation 
lag time was found to correlate significantly with LDL particle size and maximum 
diene accumulation (r = 0.33 and “0.48 respectively, both p <0.001) in the univariate 
correlation analysis. LDL particle size was significantly smaller in both NIDDM and 
hypertriglyceridaemic patients (25.23 vs 26.39 nm, p <0.0001 and 24.72 vs 25.88 nm, 
p <0.001 respectively) but the difference was not significant in the CAD group (26.92 
vs 26.24 nm，NS). The particle size was also found to correlate significantly with 
serum triglyceride (TG) concentration (r = -0.5930, p <0.001). 
Lovastatin treatment of NIDDM patients (40 mg tds) reduced serum total 
cholesterol (TC), TG, LDL-Cholesterol (LDL-C) and apolipoprotein B (apo B) 
concentrations effectively by 31，33，8 and 29 % respectively (all p <0.05). 
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concentration by an additional 36 % and increased apolipoprotein A-I (apo A-I) and 
high density lipoprotein cholesterol (HDL-C) by an additional 8 and 20 % respectively. 
Acipimox alone significantly reduced TG by 17 %, and increased HDL-C and apo A-I 
by 13 and 8 % respectively (all p < 0.05). 
Bezafibrate treatment (400 mg tds) of hypertriglyceridaemic patients reduced 
serum TG by 62 % and increased HDL-C and apo A-I by 58 and 14 % respectively (all 
p <0.01). 
Treatment with lovastatin, acipimox and bezafibrate resulted in small (< 0.35 
%) but statistically significant increased in particle size (25.32 vs 25.23, 25.53 vs 
25.23, and 25.88 vs 24.72 nm respectively, all p <0.05), and a more substantial 
increase in the oxidation lag time (67.2 vs 62.2, 72.2 vs 62.2, and 81.8 vs 68.7 min 
respectively, all p <0.05). 
Our results confirm previous reports that LDL particles are smaller and more 
susceptible to oxidation in subjects with high risk of CAD. Treatment of dyslipidaemic 
patients with hypolipidaemic drugs not only improves serum lipid-lipoprotein-
apolipoprotein profile quantitatively but also confers qualitative improvement in LDL 
particle size and oxidizability, thereby reducing the risk of CAD in primary prevention. 
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1.1 Overview on Lipids 
1.1.1 Definition and Classification of Lipids 
The term lipid applies to a heterogeneous group of compounds which have in 
common their low solubility in water, but which are more soluble in organic solvents. 
Chemically, lipids are either compounds that yield fatty acids on hydrolysis or complex 
alcohols that can combine with fatty acids to form esters. Some lipids are more 
complex containing non-fatty acid groups such as amino, sulphate, phosphoryl or sialic 
groups which increase the solubility of lipid in polar solvents. Classification of 
clinically important lipids based on their chemical structure is shown on Table 1-1. 
The major lipids of the body are fatty acids, cholesterol and its esters, 
triglycerides (TG), phospholipids and glycolipids which are essential to life. 
Physiologically, TG and fatty acids are important energy-producing and storage 
substrates. Lipids are important for absorption of fat-soluble vitamins. Many structural 
components of cell membranes are lipids such as cholesterol and phospholipids. 
Cholesterol is also the precursor of steroid hormones and bile acids. 
2 
Table 1-1. Classification of clinically important lipids based on their 
chemical structures [modified from Stein (1)]. 




Fatty acids Free fatty acids 
Prostaglandins 
Glycerol esters Triglycerides (triacylglycerols) 
Phosphoglycerides 
Sphingomyelin derivatives Sphingomyelin 
Glycosphingolipids 
3 
1.1.2 Lipoproteins and Apolipoproteins 
In human plasma all lipids, except free fatty acids (FFA), are transported in 
plasma in the form of lipoproteins. These complexes contain specific apolipoproteins, 
together with phospholipids and free cholesterol to form the outer shell of lipoprotein 
particles which solubulises the particles in the aqueous environment of plasma. The 
non-polar core of the particle contains TG and cholesterol ester (CE). Figure 1-1 
illustrates a typical lipoprotein particle with a core of hydrophobic molecules 
surrounded by a hydrophilic outershell. 
Lipoproteins can be classified according to their hydration densities into 
chylomicrons (CM), very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL), and high density lipoproteins 
(HDL). They can also be classified into five major types based on their electrophoretic 
mobilities. CM remain at the origin of the electrophoretogram since they become 
trapped in the interstices of the support medium. The (3-band on electrophoresis 
corresponds to LDL, pre p-band to VLDL, broad p to IDL, and a-band to HDL. 
Lipoproteins do not differ only in floatation density and electrophoretic mobility, but 
also in particle size, composition of lipids and apolipoproteins. Table 1-2 shows the 
properties and composition of human plasma lipoproteins. 
At least five major apolipoproteins have been described and associated with 
these lipoproteins: A, B, C, D and E. Besides being structural protein of lipoproteins, 
some apolipoproteins are important in the synthesis and release of lipoproteins, some 
are modulators of plasma enzyme activities, and others provide recognition sites for 
cell receptors which are important in lipoprotein metabolism. 
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Another apolipoprotein known as apolipoprotein(a) is also present in the 
circulation. The metabolism of this apolipoprotein appears to be regulated 
independently of other apolipoproteins. Its function is not known but increased plasma 
concentration has been associated with increased risk of atherosclerosis (2). Table 1-3 
summarises the functions and properties of human plasma apolipoproteins. 
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Figure 1-1. A typical lipoprotein particle [taken from Betteridge (3 ) with permission 
from publisher]. 
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Table 1-2. Properties and composition of human plasma lipoproteins 
[modified from Stein (1)]. 
Lipoprotein Chylomicrons VLDL IDL LDL HDL 
Density <0.95 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.21 
(kg/1) 
Particle Size 80-1200 30-80 23-35 18-25 5-12 
(nm) 
Electrophoretic 
Mobility Origin Pre-beta Broad beta Beta Alpha 
Composition 
(% by weight) 
Cholesterol 2 5-8 8 13 10 
(free) 
Cholesterol 5 11-14 22 49 38 
(esterified) 
Phospolipid 7 20-23 25 27 22 
Triglyceride 84 44-60 30 11 9 
Protein 2 4-11 15 23 21 
Apolipoprotein 
(% total) 
AI 7.4 Trace Nil Nil 67 
AE 4.2 Trace Nil Nil 22 
B-100 Trace 36.9 50-70 98 Trace 
B-48 22.5 Trace Trace Nil Nil 
C 66 49.9 5-10 Trace 5-11 
E Nil 13 10-20 Trace 1-2 
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Table 1 -3. Functions and properties of human plasma apolipoproteins 
[modified from Stein (1)]. 
Apolipoprotein Function Associated Site of synthesis 
lipoproteins 
ApoA-I LCAT cofactor HDL, Liver, intestine 
Ligand for HDL CM 
binding 
Apo A-II Modulator of lipase HDL Liver, intestine 
LCAT cofactor 
Ligand for HDL 
binding 
Apo A-IV LCAT activator HDL, VLDL, Intestine 
Ligand for HDL CM 
binding 
Apo B-100 LDL receptor ligand VLDL, LDL Liver 
Apo B-48 CM transport CM Intestine 
Apo C-I LCAT&LPL HDL, VLDL, Liver 
activator CM 
Apo C-E LCAT & LPL HDL, VLDL, Liver 
activator CM 
Apo C-m LPL inhibitor HDL, VLDL, Liver 
Modulator of CM 
uptake of CM 
&VLDL 
ApoE Ligand for LDL HDL, VLDL, Liver 
receptors CM 
IDL clearence 
Apo(a) Unknown Lp(a) Liver 
LCAT : lecitin-cholesterol acyltransferase 
LPL : lipoprotein lipase 
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f 1.1.3 Outline of Lipoprotein Metabolism 
Human lipoprotein metabolism can be divided into exogenous and endogenous 
pathways. 
In the exogenous metabolism, about 1 gram of cholesterol, in the form of free 
and esterified sterols, and 100 grams ofTG are ingested each day. These dietary lipids 
are digested and absorbed in the small intestine. Following absorption, they are re-
synthesised into chylomicrons within the enterocytes and secreted into the circulation 
via thoracic lymph. Apo A and B-48 are synthesized in enterocytes and are present in 
newly formed chylomicrons. Apo C and E together with cholesterol esters are 
transferred from HDL. Exogenous triglycerides are then removed from chylomicrons 
by the action of the enzyme lipoprotein lipase (LPL), located on the luminal surface of 
the capillary endothelium of adipose tissue, skeletal and cardiac muscle, so that free 
fatty acids are delivered to these tissues for energy production and storage. The activity 
of LPL is stimulated by apo C-II. As triglycerides are stripped off the chylomicrons, 
they become smaller. Cholesterol, phospholipids, apo A and some apo C are released 
from surfaces of the particles and taken up by HDL as shown in Figure 1-2. The CM 
remnants produced in the process are finally assimilated by apo E/apo B receptor-
mediated mechanism in the liver. 
The liver is the major organ to synthesize endogenous cholesterol and TG. In 
the endogenous pathway, they are secreted out of the liver in form ofVLDL. VLDL 
also contain apo B-100 and acquire apo C and apo E from HDL. In the circulation, 
triglycerides are also stripped off from VLDL by the action of LPL. phospholipids, 
free cholesterol and apolipoproteins are released from the surfaces and taken up by 
9 
thus converting the VLDL to IDL and LDL which have different compositions and 
properties as summarized in Table 1-2. In normal fasting plasma there is only minute 
amount of IDL. LDL is the major carrier of cholesterol in the circulation. It is 
removed by receptors present on liver and peripheral tissues for catabolism and a 
cholesterol source for their utilization. HDL is synthesized primarily in the liver and 
also in small intestinal cells as nascent HDL comprising phospholipids, cholesterol, apo 
E and apo A. The free cholesterol in extrahepatic tissue is esterified by lecithin-
cholesterol acyltransferase (LCAT), which is present in nascent HDL and activated by 
its cofactors, apo A. This esterification increases the density of the HDL particles 
which are thus converted from HDL3 to HDL2. Some cholesterol esters are carried 
back by HDL2 to IDL and then to LDL whereas some are taken up directly by the 
liver. There is also evidence that net movement of CE and TG happens between 
various lipoprotein classes in plasma in which transfer of CE and from HDL to LDL 
and VLDL in the exchange of TG (4). A simplified scheme of lipoprotein metabolism 
illustrating the endogenous and exogenous pathways is shown in Figure 1-2. 
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Fig 1-2. The exogenous and endogenous pathways of lipoprotein metabolism 
[taken from Betteridge (3) with permission from publisher]. 
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？ 1.1.4 LDL Metabolism 
LDL is the key component to determine the distribution of cholesterol between 
the liver and extrahepatic tissues. Structurally, each LDL particle is surrounded by a 
single molecule of apo B-100. The major lipid components of LDL are cholesterol 
esters, free cholesterol, triglycerides and phospholipids. About 50% of total fatty 
acids in LDL is polyunsaturated in which the majority of fatty acids is linoleic 
acid (18:2). LDL particles are also incorporated with some lipid-soluble antioxidants, 
such as tocopherol, carotene and ubiquinol-10. Table 1-4 illustrates the normal values 
of lipids, fatty acids and antioxidants in LDL. 
The study of LDL receptor by Brown and Goldstein (5,6) in 1973 provided a 
breakthrough in the understanding of LDL metabolism and its regulation. The uptake 
and degradation of LDL particle is facilitated by LDL receptors which are located on 
membrane surface. The chief role of the so-called LDL receptor pathway is to regulate 
and provide a constant source of cholesterol throughout the body to fulfill its needs, 
such as component for cell membrane, bile acid, sex hormones and corticosteroids 
synthesis. Figure 1 -3 illustrates the mechanism for the catabolism of LDL. 
The release of free cholesterol is responsible for regulating the cholesterol 
homeostasis. In the cytoplasm, it suppresses (3-hydroxy-P-methylglutaryl-coenzyme A 
reductase (HMG-CoA reductase), a rate-limiting enzyme for new cholesterol synthesis, 
thus switching off intracellular cholesterol production. It increases the activity of 
acylxholesterol acyltransferase (ACAT) to esterify excess cholesterol for intracellular 
storage as cholesterol ester. It decreases the number of LDL receptor expressed on the 
plasma membrane to prevent the over-accumulation of intracellular cholesterol from the 
circulation. Any defect or mutation in LDL receptor expression, or modulation of the 
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activity of those enzymes would affect this regulation mechanism which may lead to 
development of a clinical syndrome, such as familial hypercholesterolaemia (7). The 
inhibition ofHMG-CoA reductase activity is one of the new and powerful tools to treat 
hypercholesterolaemia (8,9) and it will be discussed later. 
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Table 1-4. Normal values of lipids, fatty acids and antioxidants in LDL [modified 
from Esterbauer (10 )]. 
Lipids Mean±SD 
(mol/mol LDL) 
free cholesterol 600 
cholesterol ester 1600 
total phospholipids 700 
triglycerides 170 
total fatty acids 2620 
total PUFAs 1283 
Individuals fatty acids 
palmitic acid 693 ±206 
palmitoleic acid 44 土 26 
stearic acid 123 ± 6 5 
oleic acid 454 土 164 
linoleic acid 1101 土 298 
arachidonic acid 153 ± 5 5 
Individual antioxidants 
alpha-tocopherol 7.26 土 2.52 
gamma-tocopherol 0.56 土 0.24 
beta-carotene 0.29 土 0.26 
alpha-carotene 0.12 土 0.14 
lycopene 0.16 土 0.11 
cyptoxanthin 0.14 土 0.13 
ubiquinol-10 0.10 土 0.10 
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Fig. 1-3. Diagrammatic representation of sequential steps in the regulatory 
mechanism for LDL catabolism via the LDL receptor pathway [taken from 
firom Betteridge (3) with permission from publisher]. 
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1. LDL receptor binds lipoprotein containing apo Bioo or E 
2. Bound LDL is internalized and transported into the cytoplasm 
3. LDL vesicles are subjected to hydrolytic enzymatic degradation, 
thereby releasing free cholesterol and amino acids for other 
utilizations. 
4. Regulatory actions on cholesterol homeostasis. 
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I 1.2 Dyslipidaemia and Cardiovascular Disease (CVD) 
1.2.1 Definition 
Dyslipidaemia is a general term to describe abnormally high and low lipid 
concentrations in blood. Over the years it has been regarded as a major contributing 
cause to coronary artery disease (CAD) which is the major type of CVD (11,12). It 
may be conveniently classified into two types related to the development of CAD. The 
first is hypercholesterolaemia which describes a definite increase in LDL-cholesterol 
(LDL-C) to a level >4.15 mmol/1, usually accompanied by a total cholesterol (TC) level 
>6.2 mmol/1 (13). The second is the so-called "atherogenic dyslipidaemia syndrome" 
which includes four different abnormalities. They are borderline high plasma TC 
concentration, hypertriglyceridaemia, small-dense LDL particles and low HDL-
cholesterol (HDL-C) concentration (14). 
1.2.2 Dyslipidaemia and CAD 
Epidemiological data indicate that for every 1 % increase in plasma TC results 
in 2-3 % increase in the risk of CAD (15). A moderately high TC concentration seems 
to be required to initiate and sustain atherogenesis. The presence of the other 
components of atherogenic dyslipidaemia does not even substantially increase the risk 
of CAD when LDL-C levels are relatively low (16,17). 
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Hypertriglyceridaemia, small-dense LDL particles and low HDL-C 
concentrations are usually co-existing. They are predisposing factors to CAD. Results 
of studies on the role of hypertriglyceridaemia as a risk factor for CAD have been 
controversial (18,19,20). However, several studies have recently demonstrated an 
association between plasma TG level and CAD (21,22). The benefits of CAD 
reduction appeared to be related to TG lowering in some lipid-lowering prevention 
trials. Hypertriglyceridaemia is a reflection of increased numbers of TG-rich 
lipoprotein particles, such as CM, VLDL and their remnants, and IDL. These 
lipoprotein particles are found to be related to the progression of CAD (23). 
The four well-known American studies, namely, Framingham Heart Study 
(FHS), Lipid Research Clinics Prevalence Mortality Follow-up Study (LRCF), 
Coronary Primary Prevention Trial (CPPT) and Multiple Risk Factor Intervention Trial 
(MRFIT), have all found an inverse correlation of plasma HDL-C and CAD mortality 
(24). A high HDL-C concentration^ >1.6 mmol/1) has been designated as a "negative" 
CAD risk factor (25). Epidemiological data indicate that for every 1 mg/dl (0.027 
mmol/1) decrease in HDL-C results in 2-3 % increase in the risk of CAD (13). It is 
possible that the participation of HDL in the reverse transport of cholesterol from tissue 
or foam cells reduces cholesterol accumulation in the arterial wall, thus retarding the 
development of atherosclerosis. 
Small-dense LDL particles have been postulated to have increased 
atherogeneicity (26). Case-control studies of patients with myocardial infarction and 
CAD have demonstrated that 40-50 % of patients have the small-dense LDL phenotype 
and it is associated with a two- to three-fold increase in CAD risk (27). The underlying 
atherogenic effect of this phenotype will be discussed later in more details. 
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： 1.2.3 Dyslipidaemia in Non-Insulin Dependent Diabetes 
Millitus Patients 
Non-insulin-dependent diabetes millitus (NIDDM) is a disease state 
characterized primarily by insulin resistance and abnormal carbohydrate and lipid 
metabolism. The disease is frequently associated with atherosclerotic complications 
which are the leading cause of morbidity and mortality among individuals with DM. 
The incidence of atherosclerotic vascular disease, including coronary artery disease 
(CAD), cerebrovascular disease and peripheral vascular disease, is higher in patients 
with DM than in the general population (28). In fact, CVD accounts for 77 % 
hospitalization and about 75-80 % deaths in DM patients (29). Several factors, such as 
dyslipidaemia, hyperglyacemia, obesity and hypertension, predispose NIDDM patients 
to atherosclerosis or its complication. Fig 1-4 illustrates the complications of NIDDM 
patients in the development of atherosclerosis including other risk factors, such as 
obesity and hypertension. Of these, the prevalence of dyslipidaemia in NIDDM is 
two- to threefold compared to the non-diabetic population. Several factors, such as the 
degree of metabolic control, severity of obesity and pattern of distribution of fat, 
presence or absence of nephropathy, and physical activity and exercise capacity, appear 
to be the primary determinants of dyslipidaemia in NIDDM. Cigarette smoking, 
alcohol intake, diet composition and drug mediation, such as diuretics and p-adrenergic 
blocker, further accentuate dyslipidaemia. The diabetic state can affect all the major 
plasma lipoproteins. This may lead not only to hyperlipidaemia, mainly elevated TG 
and low HDL-C concentrations, but also to abnormal changes in composition and 
metabolism of other lipoproteins (30). 
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(1) VLDL and its remnants in NIDDM 
The overproduction of hepatic TG and VLDL particles, and its defective 
clearance are two main causes for hypertriglyceridaemia in NIDDM. The peripheral 
insulin resistance syndrome in NIDDM patients results in the less uptake of glucose and 
less inhibition of lipolysis in adipose tissue. Therefore, the increased supply of glucose 
and FFA into the liver drives the hepatic overproduction of TG. Under normal 
circumstances, plasma insulin inhibits VLDL output by diminishing apo B and TG 
synthesis. However, such inhibitory action of insulin on hepatocytes for VLDL 
output is lost due to chronic hyperinsulinaemia in NIDDM. The release of the restraint 
of insulin on hepatic TG-rich VLDL output predisposes hypertriglyceridaemia. The 
normal function of LPL is to facilitate the lipolysis of TG in VLDL. However, the 
activity of LPL is inhibited by the elevation of plasma FFA concentration and 
hyperinsulinaemia in NIDDM. The glycosylation of apo C-E by hyperglycaemia in 
NIDDM further reduces its efficiency as a co-factor for LPL in lipolysis. These 
decrease the fractional clearance rate of VLDL-TG and result from an accumulation of 
TG-rich VLDL particles and its remnants. Furthermore, VLDL particles in NIDDM 
appear to be larger and TG-rich as compared with normal VLDL mainly caused by a 
disproportionate stimulation of VLDL-TG production relative to apo B production in 
NIDDM. Such large and TG-rich VLDL are less efficiently converted to IDL and 
preferentially removed directly from the circulation via non-LDL pathways. 
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(2) CM and its remnants in N1DDM 
The post-prandial metabolism of CM derived from the intestinal absorption of 
dietary lipids are known to be affected by fasting plasma TG concentration. Therefore a 
disturbed post-prandial CM metabolism would be expected in NIDDM patients with 
hypertriglyceridaemia. Increased competition occurs between excess VLDL and CM 
in the common lipolytic pathway. The reduced activity of LPL in NIDDM also 
decreases the binding efficiency of CM remnants to the hepatic LDL receptor-related 
protein (LRP) for the clearance. Delayed elimination of CM remnants may also result 
from increased competition with VLDL remnants (IDL) for hepatic LRP. 
(3) HDL in NIDDM 
The concentration of HDL-C depends partly on the catabolism of VLDL by 
LPL. The delipidation of VLDL in lipolytic pathway transfers surface components, 
such as phospholipids, and free cholesterol, to HDL. A reduction in LPL activity in 
NIDDM decreases the supply of these substrates for CE synthesis in HDL. The larger 
and TG-rich VLDL in NIDDM also stimulates the activity of cholesterol ester transfer 
protein (CETP) in the removal of CE from HDL to VLDL and its remnants in the 
exchange of TG which results in the formation of CE-depleted and TG-rich HDL 
particles. The distribution of HDL subfractions in diabetes is also affected. The lack of 
surface constituents in HDL impairs the maturation of smaller HDL3 to larger HDL2 
via the action of LCAT resulting in the decrease level of CE-rich HDL2. The 
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of HDL3 -apo A accelerates the clearance of HDL molecules in diabetes before they are 
matured to HDL2. 
(4) LDL in NIDDM 
The concentration of LDL-C in NIDDM are usually within the normal range but 
seems to be positively correlated with diabetic control (31). Nonenzymatic glycation 
of LDL-apo B/E in NIDDM reduces the binding efficiency of LDL to its hepatic 
receptors, thereby prolonging its half-life in the circulation. The activation of CETP 
in NIDDM also enhances the extensive heteroexchange of CE and TG between LDL 
and TG-rich VLDL occurs in the circulation. When the clearance of TG-rich VLDL in 
NIDDM is delayed, this heteroexchange of CE and TG are prolonged. The LDL 
particles are therefore frequently TG enriched and CE depleted. The acquired TG in 
LDL particles are subsequently susceptible to hydrolysis by lipases, leading to the 
overall reduction of the lipid core and resulting in the production of smaller and denser 
LDL This predominance of this atherogenic LDL phenotype is quite common in 
NIDDM and may further predispose individuals to an increased risk of CAD. Figure 
1-5 illustrates the complication of abnormalities in lipoprotein metabolism in NIDDM. 
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Fig 1-4. Diagrammatic representation of the complications of NIDDM in the 
development of atherosclerosis [modified from Oberman (32)]. 
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Fig. 1-5. Schematic presentation of abnormalities in lipoprotein metabolism in NIDDM 
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[ 1.2.4 Classification of Dyslipidaemia 
It is important to define normal plasma lipid concentrations for a proper 
identification and management of dyslipidaemia. The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel issued guidelines on recommended plasma 
lipid concentrations (13,25). The desirable values ofTC, LDL-C, TG and HDL-C are 
<5.2 mmol/1, <3.4 mmol/1, <2.3 mmol/1 and >1.6 mmol/1 respectively for those 
people over 20 years of age without CHD. Table 1-5 summaries the details of the 
NCEP guidelines for lipid abnormalities in adults. 
Fredrickson et al (1967) introduced a classification of hyperlipidaemia in terms 
of laboratory abnormalities of lipoprotein metabolism. The classification was 
subsequently revised by World Health Organisation (WHO) in 1970 (33,34). The 
WHO system provides a better understanding and communication of lipid abnormalities 
in clinical practice. Table 1-6 summaries the WHO classification of hyperlipidaemia 
and underlying lipoprotein abnormalities. Six phenotypes were defined as types I，Il-a, 
n-b, m, IV and V according to which of the lipoproteins was increased. The 
classification provides a convenient means to describe most commonly occurring 
abnormal lipoprotein profile. However, the classification does not provide an 
understanding of HDL abnormalities and the heterogeneity that exists within these 
various lipoprotein phenotypes. Despite these limitations, it is still useful for 
clinicians to have a rational approach for diagnosis and treatment. 
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Table 1-5. NCEP guidelines for plasma lipid abnormalities [adapted from (13)]. 
~ Desirable Borderline High Risk High Risk CHD 
for CHD 
TC < 5 . 2 5.2 - 6.2 > 6.2 
LDL-C <3.4 3.4-4.1 >4.1 
HDL-C >1.6 <0.9 
TG <2.3 2.3 - 4.5 >4.5 
Table 1-6. The WHO classification of hyperlipidaemia disorders [adapted from 
Thompson (35)]. 
Type TG TC LDL-C Lipoprotein 
abnormality 
I Increased Increased Decreased or Excess CM 
Normal 
I la Normal Increased or Increased Excess LDL 
Normal 
l i b Increased Increased Increased Excess LDL & 
VLDL 
m Increased Increased Decreased or Excess CM 
Normal remnants & IDL 
IV Increased Increased or Normal Excess VLDL 
Normal 
V Increased Increased Normal Excess CM 
&VLDL 
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I 1.2.5 Causes of Hyperlipidaemia 
Hyperlipidaemia may be primary (genetically determined) or secondary caused 
by a number of metabolic disorders, hormonal disturbances and drug treatment. Table 
1-7 summaries those genetic disorders relating to the Fredrichson-WHO phenotype 
system. These primary hyperlipidaemias may be monogenic or polygenic which 
involves the interactions of many genes and environmental factors. 
Various clinical disorders can also be associated with or can cause 
hyperlipidaemia. These types of secondary hyperlipidaemia may be simply classified 
into hypercholesterolemia, hypertriglyceridaemia and combined hyperlipidaemia. The 
common metabolic causes of hypercholesterolemia are hypothyroidism, nephrotic 
syndrome and obstructive liver disease. Hypertriglyceridaemia may be induced by DM, 
obesity, alcoholism and chronic renal failure. Of these disorders, hypothyroidism, 
nephrotic syndrome and chronic renal failure may also be the main causes of combined 
hyperlipidaemia. Drugs, such as beta-blockers, diuretics, retinoids or glucocorticoids, 
are also known to alter plasma lipid concentrations (32). Treatment of these disorders 
often can correct the lipid abnormality. Table 1-8 summaries various clinical disorders 
causing hyperlipidaemia. 
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Table 1-7. Genetic hyperlipidaemias [from Oberman (36)]. 
Disorders WHO Phenotype Estimated population 
Frequency 
Familial hypercholesterolemia I I-a, I I-b 1 -2/1000 
Familial defective Apo B I I-a 1-2/1000 
Polygenic hypercholesterolemia I I-a, I I-b “ 
Familial hypertriglyceridaemia IV，V 2/1000 
Familial combined hyperlipidaemia I I-a, I I-b, IV, V 3-5/1000 
Familial dysbetalipoproteinaemia I I I 1/10000 
LPL deficiency I，V Rare 
Apo C-E deficiency I, V Rare 
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Table 1-8. Causes of secondary hyperlipidaemia [modified from Oberman (36)]. 
Hypercholesterolemia Hypertriglyceridaemia Combined Hyperlipidaemia 
Common 
Hypothyroidism Diabetes Millitus Hypothyroidism 
Nephrotic syndrome Obesity Nephrotic syndrome 
Obstructive liver disease Alcohol Chronic renal failure 
Chronic renal failure 
Uncommon 
Acute porphyria Myocardial infarction Liver disease 
Pregnancy Autoimmune disorders Werner's syndrome 
Anorexia nervosa Infection Acromegaly 
Dysgolubulinemia 
Drugs 
Thiazide diuretics Beta-blockers Thiazide diuretics 
Cyclosporine Estrogens Glucocorticoids 
Glucocorticords Retinoids Retinoids 
Androgens 
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1.3 Dyslipidaemia and Atherosclerosis 
1.3.1 Pathogenesis of Atherosclerosis 
Atherosclerosis is a slow, progressive and degenerative intimal disease of 
arteries. Its development and progression involve the interactions of multiple metabolic 
and cellular processes in which disorders of lipoprotein metabolism is regarded as one 
of the main causes of atherosclerosis. The disease is characteristized by the formation 
of fibro-lipid plaques in the intima of the arteries. The first sign of atherosclerosis is 
the appearance of fatty streak on the intimal surface. It is made up of focal 
macrophage-derived lipid-filled foam cells within the intima. The progression of the 
plaque is not only to increase the number of foam cells but also the accumulation of 
extracellular cholesterol derived from the death of foam cells. The condition is 
complicated by the proliferation of smooth muscle cells and also the accumulation of 
collagen around foam cells. It results in the increase of plaque size and the thickening 
of the intima. Further complications of the atheroma includes calcification, ulceration 
and thrombosis, resulting in occlusion of the lumen and blockage of the vessel. They 
are the common causes of coronary artery disease, cerebral vascular accident and 
peripheral vascular diseases (37,38). Figure 1-6 shows the diagrammatic pictures on 






































































































































































































































































































































































































1.3.2 Mechanism of Atherogenesis 
The relationship between hypercholesterolemia and atherosclerosis has definitely 
been established. Steinberg linked the existing evidence and hypotheses to postulate the 
mechanisms in the development of atherosclerosis (40). Briefly, LDL particles become 
entrapped and modified in the intima. The modification is usually through the oxidation of 
LDL lipids and apo B-100. The subsequent uptake of these oxidized LDL (ox-LDL) by 
special scavenger receptors on macrophages is however not subjected to negative feedback 
control as mentioned in the previous section, resulting in excessive accumulation of 
cholesterol ester and the formation of macrophage-derived foam cells in the intima 
(5,40,41). A specific endothelial receptor for ox-LDL had been cloned which is a 
membrane protein that belongs structurally to the C-type lectin family (42). The disruption 
of the endothelial integrity by these foam cells evokes an inflammatory response to this 
injury, causing the adherence of platelets and the production of platelet-derived growth 
factors (PDGF). PDGF not only attracts the migration of monocytes and macrophages 
into the intima but also induces the proliferation of smooth muscle cells around the injured 
sites. Other factors, such as cigarette smoking, elevated plasma homocysteine, infection 
and hypertension, also catalyse the injury of endothelium. Repetitive cycles of such 
inflammatory response result in the formation of atherosclerotic plaques. The importance 
of LDL particles in this lipid-infiltration hypothesis and the endothelial injury hypothesis is 
represented in Figure 1-7. 
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Fig 1-7. The central role of oxidized LDL in atherogenesis [modified from 
Silverman (43)]. 
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1.3.3 Intrinsic Roles of LDL in Atherogenesis 
An elevated plasma LDL-C concentration is definitely important in the 
development of atherosclerosis. However, the infiltration and oxidation of LDL also seem 
to be critical steps in atherogenesis. Recent studies support the concept of the importance 
of LDL oxidizability and heterogeneity in the process of atherogenesis (26,27,44). 
(1) LDL Oxidizability 
LDL oxidizability is the term to describe how easy LDL particles are oxidized. 
Besides the role on the excessive loading of cholesterol into macrophages in the intima, 
ox-LDL are also suggested to have others atherogenic effects. It is chemotactic to 
monocytes and macrophages, attracting them to the site of endothelial injury where fatty 
streaks are developing (45) and also inhibiting their efflux once they have taken up ox-LDL 
(46). It is also cytotoxic to endothelial cells (47,48), disrupting their integrity and causing 
them to produce growth factors which is necessary for the development of atheromatous 
plaques (49). Evidence has shown that oxidized LDL particles were present in 
atherosclerotic lesions (50) and autoantibodies with specificity for ox-LDL were detected 
in serum (51). Studies have even demonstrated that the severity of progression of coronary 
atherosclerosis is related to the oxidative susceptibility of LDL (52). In fact, the 
oxidative behaviour is affected by the oxidant stress conditions of the surrounding 
environment as well as intrinsic properties of the particle, such as fatty acid composition, 
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Considerable interest has been focused on methods to determine LDL oxidizability 
(54,55,56). In vivo evaluation of LDL oxidation is difficult not only because the oxidation 
is likely to take place in the subendothelial space rather than in the circulation, but also the 
residence time of ox-LDL in plasma is very short. The most common in vitro approach 
for LDL oxidizability is to subject LDL to an oxidative stress and monitor continuously its 
susceptibility to oxidation. The time course of oxidation can provide useful information 
about the chemical, physicochemical and biological changes of LDL particles. These 
measurements include thiobarbituric acid-reactive substances, total lipid peroxides, 
antioxidants, relative electrophoretic mobility and conjugated dienes (55,57). 
The continuous measurement of diene formation developed by Esterbauer (55) is 
one of the most frequently used assay for assessment of LDL oxidation. It is very suitable 
for routine analysis with simple equipment and good reproducibility (58). As illustrated in 
Figure 1-8, the oxidation of unsaturated fatty acids with doubled bonds is initiated by the 
presence of copper (II) ion or cells such as endothelial cells or smooth muscle cells. The 
fatty acid hydroperoxides produced have conjugated diene bonds with UV absorption at 
234 nm. The diene versus time profile gives lag phase, propagation phase and 
decomposition phase which are the useful indices to monitor LDL oxidation. Table 1-9 
also summaries the principles and features of other methods available in the study of LDL 
oxidizability. However, these methods of LDL oxidation, unlike conjugated dienes 
formation, can not be directly and continuously measured. 
Fig 1-9 illustrates the typical time course of LDL oxidation in vitro. Kinetically, 
the initial lag phase is resulted mainly from the suppression by the endogenous antioxidants 
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the antioxidants in LDL particles are depleted and the lipid peroxidation is initiated. The 
decomposition phase is resulted from the breakdown of those labile conjugated diene and 
hydroperoxide species. 
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Fig 1-8. A diagrammatic illustration of peroxidation of LDL particles [modified from 
— Jialal (57)]. 
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Table 1-9. Methods for the Determination of LDL Oxidation (55). 
Total lipid peroxides Lipid peroxides are the major initial products of LDL 
oxidation. It can be measured by a variety of techniques, such 
as spectrophotometry, GCMS and HPLC. However, it may 
require additional instruments and the peroxide formed is 
unstable. 
Thiobarbituric Acid Malonaldehyde formed in LDL oxidation can react with 
(TBA) reactive substance TBA to generate a colour product which is measured at 532 
nm. The test is sample but is not specific for malonaldehyde. 
Antioxidants The endogenous antioxidants, such as a-tocopherol, are lost 
during LDL oxidation. The kinetic of disappearance of 
antioxidants can be monitored. Measurement of a-tocopherol 
can be performed by HPLC. However, it needs extractions 
and complex instrument. 
Relative electrophoretic The assay is based on the increase of the surface charge of 
mobility (REM) oxidized LDL during LDL oxidation which leads to a 
change in electrophoretic mobility. The REM is expressed 
the mobility change relative to the native LDL. 
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(2) LDL Particle Size Heterogeneity 
LDL particles are heterogeneous with density from 1.025 to 1.065 g/ml and particle 
diameter from 22-27 nm (59,60,61). The metabolic origin of this heterogeneity is not yet 
clearly known. It is supposed that the TG content of VLDL is the major determinant of 
LDL particle size. As mentioned in Section 1.2.3，the predominance of larger TG-rich 
VLDL particles in hypertriglyceridaemia enhances the activities of CETP and LPL in 
plasma. The former facilitates the transfer of TG to LDL in exchange of CE whereas the 
latter is responsible for the hydrolysis of TG from LDL. The overall removal of core lipid 
content in LDL results in the reduction of particle size accompanied by an increase in 
particle density as the lipid/protein ratio decreases (62). 
Studies have shown that smaller and denser LDL particles are more atherogenic and 
associated with an increased risk of atherosclerotic disease (27,63,64,65). Smaller LDL 
particle size allows a high filtration rate, resulting in a relatively higher concentration in 
the intima (49). It also has an increased susceptibility to oxidation (66,67,68), probably 
due to a relatively low vitamin E but high fatty acid content. It has a lower binding affinity 
for LDL receptor (69)， thus allowing a longer residence time in plasma and inside the 
intima which increases the chance of being oxidized. The LDL heterogeneous profile can 
be influenced not only by genetic background (26,70,71), but also environmental factors, 
such as gender, hormonal status, drugs, diet, exercise and disease state 
(72,73,74,75,76,77). 
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pooled LDL fractions or plasma were subjected to 2-16 % polyacrylamide-agarose gradient 
gel electrophoresis (GGE). Based on the GGE analysis of LDL subclasses, Austin 
identified two distinct LDL phenotypes (78). Phenotype A is characterised by a major peak 
of large , buoyant particles and a minor peak of smaller, denser LDL subspecies. In 
contrast, phenotype B is characterised by a major peak of small，dense particles and a 
minor peak of large, buoyant LDL subspecies. In general, the peak particle diameter is 
usually greater than 25.5 nm in phenotype A and smaller than 25.5 nm in phenotype B 
(78). The prevalence of phenotype B is usually higher in patients with high risk of 
atherosclerosis such as CAD and DM, and in postmenopausal women (79,80,81). Figure 
1-10 illustrates the patterns of the densitometric scan for LDL phenotypes A and B. 
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Fig. 1-10. Densitometric scans of LDL subclass phenotypes A and B after protein 
staining [modified from Austin (78)]. 
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1.4 Management of Dyslipidaemia 
The clinical and economic impacts of CVD is tremendous. Statististical data 
demonstrated that CAD, a major cardiovascular disease, remains the leading cause of 
death, almost 1 out of every 4.6 deaths, in the United States in 1993 (82). The cost of 
treatment of heart disease in the United State is estimated to be about US$ 151 billion in 
1996 (82). It is therefore important to implement risk-reduction strategies in clinical 
practice. Pharmacological intervention of dyslipidaemia is a cost-effective strategy to 
reduce mortality and improve clinical outcomes (83,84,85). 
The NCEP has established the diagnosis and treatment guidelines for those people 
over 20 years of age with elevated plasma LDL-C concentrations (12). The goals of 
therapy are to achieve the LDL-C values to <2.6 mmol/1 in CAD patients, to <3.4 mmol/1 
in patients with two or more CAD risk factors, and to <4.1 mmol/1 in all other patients. The 
treatment is first initiated by diet therapy and then followed with drug therapy if the LDL-
C values is persistently higher than the desirable goal. Table 1-10 shows the NCEP LDL-
C decision values for diet and drug therapy. 
The guidelines recommend the consumption of mono- or poly-unsaturated oils, 
poultry, fish, skimmed milk, non-fat or low fat yogurt and cheeses instead of saturated 
oils, meats and diary products rich in saturated fat. Fruits, vegetables and grains are 
encouraged. Such dietary therapy should be tried for at least six months before the 
initiation of drug therapy (86). 
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The results from some major trials with lipid-lowering drugs consistently 
demonstrate the beneficial reduction in CHD mortality and morbidity (87,88). The main 
role of lipid-lowering medication is to decrease either LDL-C，TG, or both effectively. 
Anion exchange resins, niacin, HMG CoA reductase inhibitors and fibrates are the 
four common effective medications for the treatment of dyslipidaemia. Different drugs 
have its own effectiveness, acceptance and compliance on patients. Derivatives have been 
developed from these drugs to minimize the side-effects and to enhance the overall efficacy 
(89). Figure 1-11 shows the structures of different classes of hypolipidaemic drugs. 
Table 1-10. NCEP LDL-C decision values [adapted from Schaefer (86)]. 
Patient Initiate Diet therapy Initiate Drug therapy Goal of therapy 
After Diet therapy 
Non-CHD with 
<2 CHD risk factor > 4.1 mmol/1 > 4.9 mmol/1 < 4 . 1 mmol/1 
Non-CHD with 
> 2 CHD risk factor > 3.4 mmol/1 > 4.1 mmol/1 < 3.4 mmol/1 
CHD > 2.6 mmol/L >3.4 mmol/1 < 2.6 mmol/1 
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Anion Exchange Resins 
These resins, such as cholestyramine and colestipol, bind bile acids in the intestine, 
thereby blocking the enterohepatic circulation of bile acids. They accelerate increased 
conversion of liver cholesterol to bile acids，which is followed by an increased uptake of 
circulating LDL-C in balance of the intracellular content of hepatocytes. The drugs 
effectively decrease plasma LDL-C by about 20 % with 5 % increase in HDL-C. The 
acceptance and compliance of patients are generally poor with major adverse effects of 
constipation, bloating, abdominal pain, and low absorption of other drugs. 
Niacin 
Nicotinic acid and its derivatives, such as acipimox, can effectively decrease 
plasma TG concentrations by 40 %, decrease LDL-C by 20 % and increase HDL-C by 
20 %. The mode of action is not yet clear. However, the poor acceptance and compliance 
with adverse effects of hepatatotoxicity, gastritis, hyperglyacemia and flushing are often 
observed. 
HMG CoA Reductase Inhibitors 
Lovastatin, pravastatin, simvastatin and fluvastatin all belong to this class. They can 
effectively decrease plasma LDL-C by about 35 % and TG by 20 %，and increase HDL-C 
by about 10 %. The inhibition of intracellular cholesterol synthesis by the drugs induces 
increased uptake of extracellular cholesterol to compensate for decreased production. They 
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Fibrates 
Derivatives such as gemfibrozil, clofibrate and bezafibrate, are often used in the 
lipid treatment. They can effectively decrease plasma TG by about 35 % with reduction in 
LDL-C of 10 %, and increase HDL-C by 15 %. The mechanism of action is not well 
defined but appears to inhibit VLDL synthesis and to enhance the clearance of VLDL by 
stimulating the activity of lipoprotein lipase (90). They are well tolerated with mild gastro-
intestinal disturbances, hepatotoxicity and myositis. 
The combinations of these drug therapy, such as resin with niacin, gemfibrozil 
with lovastatin, or resin with gemfibrozil, are being used increasingly to treat especially 
combined dyslipidaemias for better efficacy (89,91). Table 1-11 shows an overview of 
characteristics for some currently used lipid-lowering medications. 
NIDDM patients often have mixed hyperlipidaemia characteristerized by both 
hypercholesterolaemia and hypertriglyceridaemia . The management of dyslipidaemia in 
NIDDM more or less follows the recommendation by the NCEP. All NIDDM patients 
should undergo yearly screening of fasting lipids, glucose and HbAlc. Mild abnormalities 
of lipids, hypertension and glucose intolerance can be improved effectively by life 
modification. Treatment with hypolipidaemic drugs can be initiated if dyslipidaemia is 




Fig. 1-11. Chemical structures of different classes of hypolipidaemic drugs [taken from 
Durrington (92) with permission from publisher]. 
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Fig. 1-12. The Management of Dyslipidaemia in NIDDM [modified from Chan (93)]. 
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1.5 Aims of This Study 
The objectives of the work in this thesis are as follows : 
(1) To establish the qualitative measurements of the intrinsic properties of LDL 
particles : 
a. LDL sizing using gradient gel electrophoresis 
b. LDL oxidizability using continuous diene measurement 
(2) To compare the intrinsic properties of LDL particle size and oxidation 
susceptibility in three groups of patients and control subjects 
Group I NIDDM patients 
Group II Hypertriglyceridaemic patients 
Group m CAD patients 
(3) To study the effects of drug medication on (a) the quantity of lipids and 
lipoproteins and (b) the quality of LDL in terms of particle size and 
oxidizability. 
Medications include : 
Group I The combination of Lovastatin and Acipimox treatment in 
dyslipidaemic NIDDM patients 
Group II Bezafibrate treatment of hypertriglyceridaemic patients 
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Objective 1 was to establish the two new methods in the clinical laboratory for 
assessment of the intrinsic properties of LDL particle size and oxidizability related to 
atherosclerosis. 
Objective 2 was to study the possible atherogenic properties of LDL particles in 
various groups of subjects with high risk of atherosclerosis or already suffered from 
such condition. Studies on Groups I and E subjects should provide the information of 
the possible enhanced effects of dyslipidaemia and diabetic state on the above 
atherogenic properties that might contribute to the substantial increase risk of 
atherosclerosis. 
Objective 3 was to study the effects of hypolipidaemic drugs whether they 
could improve the quantitative aspects of lipid-lipoprotein-apolipoprotein profile. It 
should also provide information on the possible qualitative changes of the atherogenic 









2.1.1 Patients and Controls 
(1) NIDDM patients 
Patients with clinical diagnosis of non-insulin dependent diabetes millitus 
(NIDDM) were recruited from the Diabetes Millitus Clinic of the Prince of Wales 
Hospital, Shatin, Hong Kong (PWH) from May 1995 to November 1996. The 
criteria for the inclusion of patients were as follows : 
a. age from 18 to 70 years old. 
b. diabetic control with the treatment of diet alone and/or oral 
hypoglycaemic agents. 
c. (i) plasma TC >5.5 mmol/1 and TG > 2.3 mmol/1. 
(ii) dyslipidaemia persisting after diet control for 12 weeks or more. 
d. no other treatment with drugs known to interfere with glucose 
tolerance or have major effects on lipid metabolism, such as thiazide 
diuretics or B-blockers. 
e. diets and other medications remain constant throughout the study. 
f. normal liver, renal and thyroid functions, normal serum CPK activity. 
g. alcohol consumption < 50 g/day. 
h. good compliance to diet and drugs with diabetes and blood pressure 
under reasonable control (blood HbAlc < 9 %，BP < 160/95 mmHg). 
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The same number of sex and age (± 5 years) matched healthy subjects with 
fasting glucose < 6.5 mmol/1 and no symptoms of diabetes millitus were recruited 
from staff of the hospital as controls. 
(2) Hypertriglyceridaemic patients 
Patients with clinical diagnosis of hypertriglyceridaemia were recruited from the 
Lipid Clinic of the Prince of Wales Hospital from January 1995 to July 1995. The 
criteria for inclusion of patients were as follows : 
a. age from 20 to 80 years old. 
b. (i) serum TC > 6.5 mmol/1 ( or LDL-C > 4.5 mmol/1) with moderately 
elevated TG (> 2.3 mmol/1) OR 
(ii) elevated TG with normal LDL-C (<3.5 mmol//) 
1 • moderate TG (> 2.3 mmol/1) and suffered from an additional 
cardiovascular risk factors, such as diabetes or hypertension. 
OR 
2. high TG(> 6.0 mmol/1). 
c. lipid lowering diets for 6 weeks before the active treatment phase of 
the trial. 
d. no lipid treatment for more than 6 weeks before starting the active 
treatment phase of the trial. 
e. other medications for diseases, such as diabetes or hypertension, 
remain constant throughout the study. 
f. not suffered from myocardial infarction or cerebrovascular disease in 
last 6 months. 
h. normal liver, renal and thyroid functions. 
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The same number of sex and age (土 5 years) matched healthy subjects with TC 
concentration <5.5 mmol/1 and TG concentration <2.3 mmol/1 were recruited from 
from staff of the hospital as controls. 
(3) CAD patients 
Patients with clinical diagnosis of coronary artery disease proven by angiogram 
were recruited from the Cardiology Outpatient Clinic of the Prince of Wales 
Hospital from July 1995 to September 1996. They are not suffered from other 
metabolic diseases, such as diabetes millitus or hypertension. They are not on 
other drug medications known to have major effects on lipid metabolism, such 
as B-blockers or thiazide diuretics. The same number of sex and age (土 5 years) 
matched healthy subjects without symptoms and history of heart disease were 
recruited from staff of the hospital as controls. 
2.1.2 Drug Administration Trials 
(1) Lovastatin and Acipimox Therapy in NIDDM Patients 
This study was divided into three phases. Patients fulfilling the inclusion 
criteria was first started on lovastatin 40 mg tds alone in single dose daily before supper 
for 12 weeks. Acipimox 250 mg tds in single dose was then added to achieve further 
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beneficial effects on lipid parameters. This combination treatment lasted for 12 weeks. 
Lovastatin was taken off and acipimox 250 mg tds alone was given to patients for 
another 12 weeks. In each phase blood samples were taken for lipid and lipoprotein 
analysis immediately before the onset of drug administration, after 12 weeks, 24 weeks 
and finally, after 36 weeks on drugs-
(2) Bezafibrate Therapy in Hypertriglyceridaemic Patients 
Patients fulfilling the inclusion criteria was started on bezafibrate 400 mg tds in 
single dose daily after supper for 12 weeks. Blood samples were taken for lipid and 
lipoprotein analysis before the onset of drug administration and after 12 weeks on drug. 
2.1.3 Blood Samples 
After fasting overnight, venous blood was drawn and collected separately into 
plain and EDTA tubes. They were then centrifuged within 2 hours at 3000 rpm for 15 
minutes at 4�C. Serum and EDTA plasma were aliquoted and immediately preserved at 
-70°C before analysis. 
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2.1.4 Biochemicals 
All biochemicals and reagents used in this study were obtained from Sigma 
Chemical Co., St. Louis, MO 63178, USA unless specified. 
2.1.5 Solutions and Buffers 
Solutions and buffers were prepared using doubled de-ionized water and 
analytical grade reagents. The formulae and abbreviations of the solutions and buffers 
are listed below. 
(1) Phosphate Buffer Saline (PBS) 
0.02 mol/1 PBS, pH7.5 K2HP04.3H20 3.48 g/1 
KH2P04 0.80 g/1 
NaCl 8.77 g/1 
(2) Stock Copper (II) Sulphate Solution 
125 umol/1 C u 2 S 0 4 . 5 H 2 0 0 .0125 g /1 
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(3) Cholesterol Reagent Kit (Roche Diagnostic System, Basel, Switzerland) 
Ultimate V enzymatic cholesterol reagent 30 ml/ bottle 
Lipid calibrators 5 ml/bottle 
(4) EDTA Solution 
1 mmol/1 Ethylenediaminetetraacetate 
disodium salt 0.336 g/1 
(5) Sodium Chloride (NaCl) Density Solution 
1.006 g/mlNaCl NaCl 11.45 g/1 
EDTA 0.1 g/1 
(6) Coomassie Brilliant Blue (CBB) Solution 
CBB G-250 100 mg/1 
95% ethanol 50 ml/1 
Phosphoric acid 100 ml/1 
(7) Butylated hydroxytoluene (BTH) Solution 
1 mmol/1 °- 2 2 g" 
(8) Tris-Borate Buffer, pH 8.4 for Gradient Gel Electrophoresis (GGE) 
Tris(hydroxymethyl)-aminimethan 10.90 g/1 
Boric acid 4.95 g/1 
EDTA 0.875 g/1 
Sodium azide 0.195 g/1 
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(9) Barbital Buffer 
Paragon B2 Barbital Buffer, pH8.6 1.51/ bottle 
(Beckman Instruments, Fullerton, CA 94304, USA) 
5,5-diethylbarbituric acid 
(10 mmol/1) 
5,5-dimethylbarbituric acid Na salt 
(50 mmol/1) 
(10) GGE tracking dye 
Sucrose 4 g 
bromophenol blue 0.001 g 
GGE buffer 10 ml 
(11) GGE fixing solution 
sulfosalicylic acid 100 g/1 
(12) GGE Coomassie Blue stain solution 
Phast Gel Blue R 1 tablet 
Methanol 80 ml 
Distilled water 120 ml 
Acetic Acid 200 ml 
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(13) GGE destaining solution 
Methanol 3 0 0 m l / 1 
Acetic acid 100 ml/1 
Distilled water 600 ml/1 
(14) Agrose medium 
1 % Agrose 1 g/100 ml 
barbital buffer 
(15) Particle sizing marker 
HMW markers 
(Pharmacia Biotech AB, Uppsala, Sweden) 
ferritin 
thyroglobulin 0.1 ml /vial 
Latex beads 32 nm 10 ul/150 ul 
(Bangs Lab., Fishers, IN 46038-2886) GGE buffer 
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2.1.6 Apparatus and Equipment 
(1) Pharmacia PD10 column (Pharmacia Biotech AB, Uppsala, Sweden) was used 
to desalt the isolated LDL fraction for LDL oxidizability assessment. 
(2) Beckman TLX ultracentrifuge (Beckman Instruments, Fullerton, CA 94304， 
USA) was used to isolate LDL from plasma. 
(3) Roche Cobas Bio centrifugal analyser (Roche Diagnostics, Mont Clair, NJ, 
USA) was used to measure cholesterol and protein concentratiion in LDL 
fractions. 
(4) Beckman DU 650 spectrophotometer (Beckman Instruments, Fullerton, CA 
94304, USA) was used to measure optical changes during assessment of LDL 
oxidizability. 
(5) Gradipore Micrograd (MG001) electrophoresis apparatus (Gradipore Ltd, 
North Ryde, NSW, Australia) were used to determine LDL size. 
(6) Gibco BRL Horizon (model 11 • 14) electrophoresis apparatus (Grand Island, 
NY 14072, USA) was used to perform a horiztonal electrophoresis for assessing 
the characteristics of the in vitro LDL oxidizability. 
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(7) LKB 2202 laser densitometer with LKB 2220 integrator (LKB-Produkter AB， 
Bromma, Sweden) were used to scan and record the gel pattern for LDL 
sizing. 
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f 2.2 Methods 
2.2.1 General Clinical Biochemistry Tests 
Serum cholesterol (TC) and triglycerides (TG), and plasma glucose were 
measured on a Hitachi 911 Chemistry Analyser (Boehringer Mannheim GmbH, 
Mannheim, Germany). High density lipoprotein cholesterol (HDL-C) was also 
determined on Hitachi 911 after precipitation of VLDL and LDL with phosphotungstic 
acid reagent using the manufacturer's procedure. Serum renal function tests, liver 
function tests and bone profile were performed using Dimension AR Chemistry 
Analyser (Wilmington, Delaware 19898，USA). 
2.2.2 Apolipoprotein Assays 
Serum apo A-I and apo B-100 were measured by immunonephelometry using 
the Beckman Array nephelometer (Beckman Instruments). The reagents, IFCC 
calibrator and controls used were also from Beckman Instruments. This nephelometer 
measures the peak rate of changes in intensity of scattered light generated by particles 
which are formed by immune complexes of the specific antibody and antigen in the 
mixture. 
Apolipoprotein(a) [Apo(a)] was assayed by immunoradiometric assay using the 
Mercodia apo(a) commercial kit (Mercodia AB, Uppsala, Sweden). It is a solid phase 
two-site immunoradiometric assay in which two monoclonal antibodies are directed 
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against separate antigenic determinants on the apo(a) molecule. During incubation 
apo(a) in the sample reacts with 125I-anti-apo(a) antibodies and anti-apo(a) antibodies 
bound to Sepharose particles. The formed antibody-antigen complex is separated from 
excess tracer by addition of a decanting solution followed by centrifugation and 
decanting. The radioactivity in the pellet measured by gamma counter is directly 
proportional to the concentration of apolipoprotein(a) in the sample. 
2.2.3 Ultracentrifugation of LDL Fraction 
The procedure was adapted from Chung and McDowell (94,95). LDL was 
isolated by a density gradient centrifugation using the Beckman TLX ultracentrifuge 
with a fixed angle rotor TLA 120.2. EDTA plasma (0.35 ml) was added to a 
polycarbonate centrifuge tube (No, 343775) containing 0.173 g dried potassium 
bromide, converting the density of plasma to 1.23 g/rnl. This was then overlaid with 
0.8 ml NaCl (1.006 g/ml) and centrifuged at 527,000 g for 140 minutes at 4°C. A 
discrete yellow coloured LDL band was located approximately one-third from the top 
of the tube. The top of the tube containing greasy fraction was first removed by using 
Beckman splicer. The LDL fraction was then aspirated and adjusted to final volume of 
0.35 ml. The fraction was kept in an ice bath for further analysis within half an hour. 
All samples were analysed in duplicate that 0.7 ml of LDL fraction from each subject 
was finally collected for further analysis. 
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2.2.4 De-Salting of LDL Fraction 
Potassium bromide and other small molecules were removed by molecular size 
exclusion chromatography using pre-packed column containing Sephadex G25 (PD-10, 
Pharmacia Biotech, Uppsala, Sweden). Total 10 aliquots of about 0.5 ml desalted 
fractions were collected and kept at ice bath for cholesterol measurement within half an 
hour. 
2.2.5 Quantitative Determination ofLDL-Cholesterol and 
Protein Fractions 
The cholesterol content of neat LDL fraction before desalting and those ten 
desalted aliquots were measured by using Roche Cobas Bio Analyser with Roche 
Ultimate V cholesterol reagent. The calibrators of 4.17 mmol/1 and 2.08 mmol/1 were 
used for construction of a 2-point standard curve by the analyser. The protein content 
of neat LDL fraction before desalting was measured by using Roche Cobas Bio 
Analyser with modified Bradford method (96). For those desalted aliquots, the two 
with highest concentrations of cholesterol were pooled together and assayed for 
cholesterol. This pooled desalted LDL fraction was ultimately used for the in vitro 
LDL oxidation experiment. A new standard curve for two calibrators of 2.08 mmol/1 
and 1.04 mmol/1 was used because the cholesterol range of the LDL fraction was 
expected between 0.5 mmol/1 and 1.5 mmol/1. The parameter settings for cholesterol 
and protein measurements were shown in Appendix I. 
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[ 2.2.6 In Vitro Assessment of LDL Oxidizability 
The method was modified from McDowell and Jenkins (95,97). Briefly, the 
pooled desalted LDL fraction was diluted with PBS and standardized to 0.15 mmol/1 
cholesterol for the in vitro assay. Sample of 1.2 ml was mixed with 50 ul CuS04 
solution (final concentration 4 umol/L) in quartz curette which had been sonicated and 
washed with distilled water several times. The reaction was monitored at 30 °C for 4 
hours using a thermo-controlled Beckman DU650 spectrophotometer. The absorbance 
at 234 nm was recorded every 2 minutes over the period. Samples were run in 
duplicate. An aliquot LDL sample from an volunteer was also run in parallel to check 
the quantitative variation. Data were then transferred to Microsoft Excel file for 
processing. The calculations of lag time, maximum propagation rate and diene 
accumulation in the oxidation experiment are described in Appendix II. 
2.2.7 Electrophoretic Gel Pattern of LDL Fraction During In Vitro 
Oxidizability 
In order to study the physio-structural changes of LDL particles during the 
oxidation process, an experiment was set up as described above in Method 2.2.6. 
However, aliquots of 120 ul were taken out from the reaction mixture at 0 hour, 2 
hour, 4 hour and 24 hour respectively. The aliquots were then mixed with 15 ul of 
each EDTA buffer and BTH solution, thereby stopping the reaction at these particular 
intervals. The aliquots were kept at 4 °C until electrophoresis using 1 % agrose gel 
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with barbital buffer (pH8.6) in the Gibco BRL Horizon Electrophoresis apparatus at 
200 V for 2 hours (54). The gels were then visualized by staining with Coomassie Blue 
and decolourizing with destaining solution (see below for details). 
2.2.8 Study of LDL Particle Size 
The electrophoresis apparatus and gradient gel were supplied by Gradipore Ltd. 
The method was modified from the manufacturer' instruction (98). Briefly, aliquots of 
10 U1 salted LDL sample, Pharmacia HMW markers or 32 nm latex beads were mixed 
with 10 ul GGE tracking dye separately. The samples were then pipetted into TBE-
buffered 3-13 % native PAGE 3 mm gel (Gradipore GS313) inside Gradipore 
Micrograd electrophoresis apparatus (MG001). The maximum of eight samples 
together with the two calibration markers were run in each gel. Electrophoresis was 
carried out at 4 °C for 18 hours in which 100 V was applied for the first hour and 200 
V for next 17 hours. The gel was first fixed with 5 % sulfosalicylic acid for 1 hour and 
stained with Coomassie Blue for 3 hours. It was then destained with destaining 
solution (methanol/acetic acid/water) for 3 hours and with distilled water overnight. 
Finally the gel was scanned with LKB Laser Densitometer (model 2202) and the gel 
pattern was recorded with LKB integrator (model 2220). The parameter settings of the 
densitometer and integrator are shown in Appendix HI. The log of diameter against 
distance travelled by the three markers (ferritin 12.2 nm and thyroglobulin 17.0 nm and 
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latex beads 32.0 nm) were plotted to construct the calibration curve for determining the 
diameter of LDL sample. A LDL aliquot sample from a volunteer was applied in a 
separate lane to check the quantitative variation for each run. 
2.2.9 Statistical Analysis 
Statistical analysis of data obtained from the study was carried out with SPSS 
statistical software version 6.0. All results were presented as median with interquartile 
range (25th to 75th percentile) unless otherwise specified. The sample size in this 
study was small (n <25) that the population samples might not follow a Guassian 
distribution. The non-parametric procedures used in this study are valid under fairly 
general conditions that they should certainly be used whether there is any doubt about 
the appropriateness of assuming Guassian distribution. Therefore, the non-parametric 
Mann-Whitney test was chosen for comparison of difference between patient and 
control groups. The non-parametric Sign test was chosen for comparison of difference 
between the before and after of the drug treatment within the group. The Pearson's 
correlation test was used to test the correlation of selected variables. A probability (p) 






3.1 Quantitative Determination and Standardization of LDL 
Fractions 
Figure 3-1 illustrated an example of the cholesterol profile of LDL desalted 
fractions. Ten 0.5-ml desalted fractions were collected from each LDL sample. The 
two fractions with highest concentrations of cholesterol (Fractions 5 and 6 in this case) 
were pooled together and re-assayed for cholesterol. The final cholesterol 
concentration of this pooled desalted fraction was then diluted to 0.15 mmol/1 with PBS 
for the in vitro oxidation experiment. The inter-assay coefficient variation (CV) of 
cholesterol measurement, using method described in Section 2.2.5, from the two 
pooled control samples were 2.0 % and 2.8 % (n=24) respectively. 
The inter-assay CV of LDL-C concentration, using ultracentrifugation method 
described in Section 2.2.3, from a control sample was 2.9 % (n=25). The correlation 
of the LDL-C obtained by ultracentrifugation and the Fredewald calculation was 
compared in those samples in the study with TG concentration < 4.5 mmol/1. It was 
shown that the LDL-C concentration obtained by ultracentrifugation method (x) has a 
lower value when compared to the Fredewald calculation (y) in 50 samples (y = 1.14 x 
+ 0.015). They were still reasonably well correlated with each other (r=0.95, p 
<0.0001) with percentage difference of 12.5 土 7.2 % (mean 土 SD) as shown in Figure 
3-2. The values of LDL-C reported in the study were all obtained by 
ultracentrifugation. 
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3.2 In Vitro Assessment of LDL Oxidizability 
Figure 3-3 shows the typical spectrophotometric results from a dyslipidaemic 
patient before and after bezafibrate treatment in the LDL oxidation experiment. The 
kinetics of conjugated diene formation was measured by monitoring absorbance (OD) 
at 234 nm. The patterns can be characteristized by three phases. The lag time was 
initial period with no change in OD 234 nm. It was followed by a propagation period 
with a rapid increase in absorbance due to conjugated lipid diene formation. The final 
stage was a decomposition period with a gradual decrease in OD 234 nm due to the 
decomposition of unstable lipid dienes. As illustrated in this figure, there was an 
increase in lag time and a decrease in maximum diene accumulation after bezafibrate 
treatment, resulting in an increased resistance to oxidation. The inter-assay CV of 
the lag time using a control LDL sample was 5.1 % (n=20，72.51 土 3.97 min). 
3.3 Electrophoretic Pattern of LDL during In Vitro 
Oxidizability 
Figure 3-4 shows the electrophoretic patterns of the same LDL fraction running 
in the agrose gel during it was subjected to the in vitro oxidation at different time 
intervals. The changes of the relative electrophoretic mobility (REM) of LDL fraction 
before and after 2 hours, 4 hours and 24 hours of oxidation were calculated from 
dividing the migration distance at these particular intervals by that at 0 hour. There was 
only little migration between 0 hour and 2 hour (REM 1 vs 1.06)，but the difference 
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became obvious when compared with values at 4 and 24 hours (REM 1.6 and 2.2 
respectively, Fig. 3-4). It was found that the migration distance of LDL fraction was 
increased with the oxidation time. 
3.4 LDL Sizing 
Figure 3-5 shows the typical LDL electrophoretic pattern from different 
individuals. Lanes 1 and 2 were the two markers (Lane 1: 32.0 nm latex bead marker; 
Lane 2: Pharmacia HMW markers) for calibration curve. The 3-point calibration curve 
using ferritin (12.2 nm), thyroglobulin (17.0 nm) and latex beads (32.0 nm) was 
shown in Figure 3-6. 
LDL bands in lanes 3，4，5，6 and 7 were from different individuals. There 
might be more than one band in each individual as shown in Lane 7 in which the 
dominant band was used to define the LDL particle size in the study. The inter-assay 
CV of a volunteer's LDL sample was 1.8 % (n=29, 25.26 士 0.46 nm). 
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Fig. 3-3. The absorbance profile of LDL fraction in the in vitro oxidation experiment 
from a h^ertriglyeridaemic patient before and after bezafibrate treatment. 
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3.5 Correlations of Triglycerides Concentration, LDL Particle 
Size and Oxidizability 
Pearson's correlation test was used to examine possible associations between TG, 
LDL particle size, and LDL oxidizability in terms of lag time and maximum diene 
accumulation. The relevant data from dyslipidaetnic patients (ie. groups I and II) before 
treatment, CAD patients and controls were grouped together to perform the analysis. The 
total sample number was 108. 
It was found that LDL particle size significantly correlated with TG concentration 
(r= -0.5930, p <0.001). This correlation was still significant even after controlling for 
LDL-C and TC (r= -0.4199 and p <0.001). The plots of this univariate correlation and 
LDL particle size distribution in different patient and control groups are shown in Figure 
3-7a and 3.7b, respectively. 
LDL particle size also significantly correlated with oxidation lag time (r= 0.3298, p 
<0.001) but the correlation was lost after statistically controlling for either individual 
factor of LDL-C, TC, TG and maximum diene accumulation or in combination. 
Oxidation lag time was also found significantly correlated with maximum diene 
accumulation (r= -0.4754, p <0.001). This correlation was still significant even after 
statistically controlling for TC, LDL-C, PS and TG (r=-0.2398 and p <0.05). 
These subjects were also divided into two groups in terms of their LDL particle size 
at a cut-off value of 25.5 nm. The mean differences in the oxidation lag time and 
maximum diene accumulation between these two groups were compared by using the 
independent t test. Those subjects with smaller LDL particle size (<25.5 nm) were more 
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susceptible to LDL oxidation in terms of shorter lag time and higher concentration of diene 
accumulation than those with larger LDL particle size ( 67.2 vs 75.2 min and 1.75 vs 
1.60 xlO"4 mol/ mmol LDL-C respectively, both p <0.001). Figure 3-8 shows the 
distribution of the values of the lag time in these two groups. 
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Fig. 3-6. The calibration curve of LDL sizing 
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Fig. 3-7. A plot of LDL particle size with serum TG concentration. 
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I Fig. 3.7b. A plot of LDL particle size distribution in different patient and control 
groups. 
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Fig. 3-8. The distribution of oxidation lag time at a cut-off LDL particle size of 25.5 nm 
with mean 土 SD 
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3.6 Diabetes Millitus 
3.6.1 NIDDM & Control 
Twenty four patients (8 males and 15 females) and the same number of sex and 
aged-matched controls were recruited as described in Section 2.1.1. Three patients were 
discontinued after lovastatin treatment because they did not follow the proper instruction 
for oral medications of lovastatin and acipimox in the combined treatment. All of them 
except one were taking an oral hypoglyacemic drug (such as metformin and diamicron). 
Among them, nine patients were concurrently suffering from hypertension whereas five 
suffering from CAD. They were all remained on appropriate medications during the whole 
study. 
Compared to the control group (Table 3-1)，NIDDM patients had significantly 
higher median concentrations of plasma TC, TG and apo B (6.40 vs 5.10 mmol/1, 4.40 vs 
0.95 mmol/1, and 142 vs 100 mg/dl respectively, both p <0.0001) but a lower HDL-C 
concentration (0.97 vs 1.36 mmol/1, p <0.001). The LDL-C and others lipoproteins (apo A 
and apo(a)) did not give a significant difference between the two groups (p >0.05). 
The physiochemical characteristics of LDL are shown in Table 3-2. No significant 
difference was found in LDL-C, LDL-Protein (LDL-P) and its ratio. For the in vitro 
oxidizability, NIDDM group had significant shorter lag time (62.2 vs 75.5 min, p 
<0.0001) and greater maximum diene accumulation (1.70 vs 1.55 x 10"4 mol diene/mmol 
LDL-C, p <0.001) than that in control group. The maximum propagation rate was 
however found no significant difference between the two groups. It also found that 
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NIDDM patients had a significantly smaller LDL particle size than that in control 
group (25.23 vs 26.39 nm, p < 0.0001). 
Table 3-1. Serum lipid-lipoprotein-apolipoprotein profile of NIDDM patients and 
controls 
Parameters NIDDM group Control group p value 
Age 61 60 NS~ 
(49-65) (52-63) 
TC 6.40 5.10 <0.0001* 
(mmol/1) (6.05-8.00) (4.15-6.30) 
TG 4.40 0.95 <0.0001* 
(mmol/1) (2.65-6.5) (0.63-1.62) 
LDL-C 2.71 2.66 NS 
(mmol/1) (2.07-3.08) (2.44-3.30) 
HDL-C 0.97 1.36 <0.001* 
(mmol/1) (0.80-1.19) (1.02-1.64) 
Apo-AI 157 164 NS 
(mg/dl) (135-176) (125-175) 
Apo-B 142 100 <0.0001* 
(mg/dl) (125-155) (84-125) 
Apo(a) 105 115 NS 
(U/l) (61-300) (83-190) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference between NIDDM and controls groups (n=24) 
NS : no significant difference 
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Table 3-2. Characterization of isolated plasma LDL of NIDDM patients and controls 
Parameters NIDDM group Control group p value 
LDL-C Z71 2M NS~ 
(mmol/1) (2.07-3.08) (2.44-3.30) 
LDL-P 576 611 NS 
(mg/1) (474-688) (489-789) 
LDL C/P 1.77 1.74 NS 
(1.10-2.30) (1.54-1.97) 
LDL Oxidizability 
Lag Time 62.2 75.5 <0.0001* 
(min) (56.6-69.6) (72.2-81.2) 
Max. Propagation Rate 3.10 3.12 NS 
(xl0"6mol diene formed / (2.70-3.52) (2.87-3.30) 
min/mmol LDL-C) 
Max. Diene Formed 1.70 1.55 <0.001* 
(xlO-4 mol/mmol LDL-C) (1.58-1.90) (1.50-1.60) 
LDL Particle Size 25.23 26.39 <0.0001* 
(nm) (24.77-25.47) (25.70-26.70) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference between NIDDM and control groups (n=24) 
NS : no significant difference 
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3.6.2 Effect of Drug Treatment on Serum Lipid-Lipoprotein-
Apolipoprotein Profile 
During lovastatin therapy (WkO vs Wkl2), serum TC, TG, LDL-C, apo B 
concentrations were found significantly decreased by 31 %, 33 %, 8 % and 29 % 
respectively from the corresponding median values of 6.40 to 4.40 mmol/1, 4.40 to 2.95 
mmol/1, 2.71 to 2.00 mmol/1, and 142 to 103 mg/dl (all p <0.05). Although the median 
values of HDL-C and Apo A-I were not much changed before and after lovastatin treatment 
(HDL-C of 0.97 vs 1.00 mmol/1 and Apo A-I of 157 vs 154 mg/dl), they were found 
significantly increased after treatment (all p <0.05). 
The addition of acipimox resulted in an additional 36 % reduction of serum TG 
concentration (2.95 vs 1.90 mmol/1) and an increase in HDL-C and Apo A-I by 30 % and 
8 % ( 1.00 vs 1.30 mmol/1 and 154 vs 167 mg/dl respectively), although the significant 
difference was only found in HDL-C (p <0.05). Concentrations of serum TC and LDL-C 
did not have any obvious changes. However, the combined therapy induced a significant 
increase of apo(a) concentration when compared to Weeks 0 and 12 (all p <0.05). 
After the removal of lovastatin therapy (Wk36), median concentrations of TC, TG, 
LDL-C and apo B were significantly raised by about 39 %, 95 %, 43 % and 42 % 
respectively ( all p < 0.01) when compared to the combination therapy of lovastatin and 
acipimox. Apo A-I concentration was also statistically decreased (p <0.05) although there 
was not much changed in median value. When compared to the baseline (Wk36 vs WkO), 
acipimox significantly decreased median TG concentration by 17%, and increased HDL-
C by 13 % and apo A-I by 8 % (all p <0.05). Concentrations of glucose and HbAlc 
were not significantly changed during the whole period of drug treatment. The details of 
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the changes of serum lipid-lipoprotein-apolipoprotein profile and glycaemic control were 
shown in Table 3-3. 
During lovastatin therapy (WkO vs Wkl2), the median concentration of LDL-P 
mass was significantly decreased by about 21 % from 576 to 454 mg/1 without affecting 
LDL C/P ratio. The LDL oxidation lag time and particle size were also significantly 
increased from 62.2 to 67.2 min. (p <0.05), and 25.23 to 25.32 nm (p <0.0001) 
respectively. 
During the combination therapy of lovastatin and acipimox (Wk 24)，there was 
about 13 % further decrease in median concentration of LDL-P (454 vs 396 mg/1, p 
<0.01) accompanied by an increase of LDL-C/P ratio (1.64 vs 2.61). The ratio was 
significantly increased when compared to the baseline (p <0.05). The combined therapy 
also enhanced a non-significant increase in the LDL oxidation lag time and particle size 
than that in Wkl2 (72.0 vs 67.2 min and 25.58 vs 25.32 nm respectively). The difference 
was still significant when compared to the baseline (both p <0.05). 
After the removal of lovastatin from the combined therapy (Wk36), the median 
value of LDL-P mass increased dramatically by 50 % from 396 to 595 mg/1 (p <0.001) 
which was close to the baseline level. There were no significant changes in the LDL 
oxidation lag time and particle size when compared to Wk24. However they were 
significant different from the baseline (p <0.001). There were no statistical changes in the 
maximum diene accumulation and propagation rate during the whole period of drug 
treatment. The details of the change of those parameters are shown in Table 3-4. 
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Table 3-3. Serum lipid-lipoprottein-apolipoprotein profile and glycaemic control of 
NIDDM patients during drug treatment. 
Parameters Baseline Wkl2 Wk24 Wk36 
(n=24) (n=24) (n=21) (n=21) 
lovastatin lovastatin + acipimox acipimox 
TC 6 ^ 4 0 ~ 4.40**** 4.80**** 6.66+ 
(mmol/1) (6.05-8.00) (5.00-5.55) (4.30-5.50) (5.60-7.00) 
TG 4.40 2.95**** 1.90** 3.70**+ 
(mmol/1) (2.65-6.50) (1.95-4.45) (1.40-3.20) (2.00-4.20) 
LDL-C 2.71 2.00* 2.08* 2.97+ 
(mmol/1) (2.07-3.08) (1.76-2.50) (1.77-2.55) (2.21-3.38) 
HDL-C 0.97 1.00** 1.30****# 1.10*+ 
(mmol/1) (0.80-1.20) (0.92-1.28) (1.05-1.42) (0.93-1.26) 
Apo-AI 157 154** 167** 169* 
(mg/dl) (135-176) (143-179) (150-180) (136-176) 
Apo-B 142 103**** 100**** 142+ 
(mg/dl) (125-155) (92-122) (84-120) (116-155) 
Apo(a) 105 72 100**# 90 
(U/l) (61-300) (54-357) . (64-337) (64-326) 
Glucose 8.6 8.9 7.5 7.6 
(mmol/1) (7.5-9.4) (7.9-9.7) (7.1-8.3) (6.1-8.8) 
HbAlc 7.6 7.8 7.9 8.0 
(% Total Hb) (7.2-8.0) (7.4-8.5) (7.5-8.3) (7.3-8.4) 
Data are presented as Median (Interquartile Range) 
p < 0.05 
“**，， p<0.01 
“****，，p < 0.0001 when compared to the baseline (Week 0) 
"#" p <0.05 when compared to week 12 
‘‘+，， p <0.05 when compared to week 24 
Significant level at p <0.05 
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Table 3-4. Characterization of isolated plasma LDL in NIDDM patients during drug 
treatment. 
Parameters Baseline Wkl2 Wk24 Wk36 
(n=24) (n=24) (n=21) (n=21) 
I ^ C 2JI 2^08* 2.97+ 
(mmol/1) (2.07-3.08) (1.76-2.50) (1.77-2.55) (2.21-3.38) 
LDL-P 576 454* 396** 595+ 
(mg/1) (474-688) (350-542) (294-527) (492-709) 
LDL C/P 1.77 1.64 2.61* 1.72 
(1.10-2.30) (1.38-2.13) (1.48-3.03) (1.24-2.12) 
LDL Oxidizability 
Lag Time 62.2 67.2* 72.0*** 72.2*** 
(min) (56.6-69.6) (62.0-80.2) (69.4-77.7) (65.2-75.1) 
Max. Propagation Rate 3.10 2.62 2.74 2.94 
(Xl0-6mol diene formed/ (2.71-3.53) (2.23-2.92) (2.55-3.01) (2.72-3.26) 
min/mmol LDL-C) 
Max. Diene Formed 1.70 1.69 1.64 1.53 
(xio-4 moi/mmol LDL-C) (1.58-1.89) (1.56-1.94) (1.54-1.88) (1.47-1.67) 
Particle Size 25.23 25.32* 25.58* 25.53* 
(nm) (24.77-25.47) (24.92-25.94) (25.03-26.18) (25.23-25.88) 
Data are presented as Median (Interquartile Range) 
‘‘*” p < 0.05 
“**’， p<o.01 
“***” p < o.oOl when compared to the baseline (Week 0) 
"#" p <0.05 when compared to week 12 
‘‘+” p <0.05 when compared to week 24 
Significant level at p <0.05 
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3.7 Hypertriglyceridaemic Patients 
3.7.1 Patients & Controls 
Fifteen patients (5 males and 10 females) and the same number of sex and age-
matched controls were recruited as described in Section 2.1. Among them, seven 
patients concurrently suffered from hypertension. Four patients suffered from 
diabetes millitus and were not included in the comparison analysis with the control 
group (see discussion for more details). 
Compared to the control group (Table 3-5), median concentrations of serum 
TC, TG and apo B were expected significantly higher (6.90 vs 4.60 mmol/1, 6.43 vs 
0.77 mmol/1, and 138 vs 92 mg/dl respectively, all p <0.001) whereas apo A-I 
concentration was significantly lower in patient group (142 vs 161 mg/dl, p <0.05). 
However, median concentration of LDL-C was lower in the patients group(2.01 vs 
2.68 mmol/1, p <0.01). Concentrations of HDL-C and apo(a) between patients and 
controls group were not found at significantly difference. 
As shown in Table 3-6，patient group had a significantly lower LDL-C/P ratio 
than control (1.16 vs 1.85, p <0.001)，probably resulting from a lower concentration 
of LDL-C (2.01 vs 2.68 mmol/1, p <0.01) but a higher concentration ofLDL-P(618 vs 
518 mg/1, p >0.05). The LDL particle size was also significantly smaller in patient 
group than that in control group (24.72 vs 25.88 nm, p <0.001). For the in vitro 
oxidizability, the lag time was non-significantly shorter in patient group (68.7 vs 
75.4 min, p >0.05) without no much difference in maximum propagation rate. The 
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maximum diene accumulation was however significantly higher in patient group than 
in control group (1.85 vs 1.60 xlO"4 mol/mmol LDL-C, p <0.05). 
3.7.2 Bezafibrate Treatment 
During bezafibrate therapy (Table 3-7), serum TG concentration decreased 
dramatically from a baseline median value of 5.83 to 2.20 mmol/1 (p <0.0001) 
without no much change in TC concentration. LDL- C and HDL-C median 
concentrations were also increased from 2.01 to 2.75 mmol/1 and 0.68 to 1.39 mmol/1 
respectively (both p <0.05). Apo A-I and apo B concentrations were also increased in 
response to bezafibrate therapy from 133 to 152 mg/dl and 147 to 169 mg/dl 
respectively but the difference was only found significant in apo A-I (p <0.001). 
As shown in Table 3-8, there was a significant increase in LDL-C/P ratio 
(1.28 vs 1.74, p <0.01)， probably resulting from a significant increase of LDL-C. 
The LDL particle size was also significantly increased from 24.72 nm to 25.47 nm 
(p <0.001). Figure 3-8 shows the electrophoretic change of LDL bands from the 
three patients before and after bezafibrate treatment. There was an obvious increase 
in L d L particle size in subjects B and C after bezafibrate treatment. 
For LDL oxidizability, lag time was significantly increased from 68.7 to 
81.8 min (p <0.05), together with a decrease of maximum propagation rate and diene 
accumulation from 2.98 to 2.74 x 10"6 mol/min/mmol LDL-C and 1.77 to 1.51 x 10"4 
mol/mmol LDL-C respectively (both p <0.05). 
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Table 3-5. Serum lipid-lipoprotein-apolipoprotein profile of 
hypertriglyceridaemic patients and controls. 
Parameters Patients Controls p value 
Age 56 52 NS 
(years) (48-61) (47-56) 
TC 6.90 460 <0.0001* 
(mmol/1) (6.50-7.60) (4.10-5.00) 
TG 6.43 0.77 <0.0001* 
(mmol/1) (4.12-9.24) (0.68-1.58) 
LDL-C 2.01 2.68 <0.01* 
(mmol/1) (1.36-2.17) (2.36-2.85) 
HDL-C 0.98 1.12 NS 
(mmol/1) (0.80-1.21) (1.06-1.47) 
Apo-AI 142 161 <0.05* 
(mg/dl) (116-146) (138-171) 
Apo-B 138 92 <0.001* 
(mg/dl) (136-166) (87-112) 
Apo(a) 94 96 NS 
(U/l) (52-327) (66-151) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference between patient and control groups (n=l 1) 
NS : no significance difference 
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Table 3-6. Characterization of isolated plasma LDL in hypertriglyceridaemic 
patients and controls. 
Parameters Patients Controls p value 
LDL^C 2M 2M <0.01* 
(mmol/1) (1.36-2.17) (2.36-2.85) 
LDL-P 618 518 NS 
(mg/1) (581-722) (472-617) 
LDL-C/P 1.16 1.85 <0.001* 
(0.78-1.45) (1.74-2.07) 
LDL Oxidizability 
Lag Time 68.7 75.4 NS 
(min.) (59.3-76.2) (67.9-78.8) 
Max. Propagation Rate 3.29 3.14 NS 
(xl0"6mol diene formed / (2.68-3.49) (3.01-3.40) 
min/mmol LDL-C) 
Max. Diene Formed 1.85 1.60 <0.05* 
(xl0"4 mol/mmolLDL-C) (1.71-2.15) (1.55-1.70) 
LDL Particle Size 24.72 25.88 <0.001* 
(nm) (24.38-24.92) (25.33-26.27) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference between patient and control groups (n=l 1) 
NS : no significance difference 
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Table 3-7. Changes in serum lipid-lipoprotein-apolipoprotein profile of 
hypertriglyceridaemic patients during bezafibrate therapy. 
Parameters Before treatment After treatment p value 
WkO Wkl2 
TC 6.90 6.30 NS 
(mmol/1) (6.05-7.35) (5.95-6.85) 
TG 5.83 2.20 <0.0001* 
(mmol/1) (3.71-8.90) (1.72-2.62) 
LDL-C 2.01 2.75 <0.05* 
(mmol/1) (1.38-2.39) (2.38-3.44) 
HDL-C 0.88 1.39 <0.01* 
(mmol/1) (0.80-1.11) (0.93-1.53) 
Apo-AI 133 152 <0.001* 
(mg/dl) (118-143) (136-179) 
Apo-B 147 169 NS 
(mg/dl) (136-171) (134-186) 
Apo(a) 78 213 <0.05* 
(U/l) (45-327) (85-450) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference (n=15) 
NS : no significance difference 
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Table 3-8. Changes in physiochemical characteristics of plasma LDL in 
hypertriglyceridaemic patients during bezafibrate therapy. 
Parameters Before Treatment After Treatment p value 
WkO Wkl2 
LDL^C 2 M 2 J 5 <0.05* — 
(mmol/1) (1.38-2.39) (2.38-3.44) 
LDL-P 611 649 NS 
(mg/1) (565-722) (609-736) 
LDL-C/P 1.28 1.74 <0.01* 
(0.83-1.63) (1.48-1.99) 
LDL Oxidizability 
Lag Time 68.7 81.8 <0.05* 
(min.) (60.3-73.3) (67.7-87.3) 
Max. Propagation Rate 2.98 2.74 <0.05* 
(xl0"6mol diene formed/ (2.71-3.38) (2.48-2.83) 
min/mmol LDL-C) 
Max. Diene Formed 1.77 1.51 <0.05* 
(xl0'4 mol/mmol LDL-C) (1.62-2.13) (1.43-1.61) 
LDL Particle Size 24.72 25.47 <0.01* 
(nm) (24.38-24.92) (25.12-26.33) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference (n=15) 
NS : no significance difference 
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Fig. 3-8. The GGE pattern of plasma LDL fraction from different individuals 
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3.8 CAD Patients 
3.8.1 CAD & Control 
Fifteen patients (9 males and 6 females) and the same number of sex and age-
matched controls were recruited as described in Section 2.1 • They were screened from 
about 150 CAD patients they were not suffered from other metabolic diseases such as 
diabetes millitus, hypertension or dyslipidaemia. 
The serum lipid, lipoprotein and apolipoprotein profile were shown in Table 3-
9. There were no significant difference in the median concentrations of TC, TG, 
HDL-C, LDL-C and apo B in patient and control groups (all p >0.05). However, the 
CAD patient group had a significant lower median concentration of apo A-I (122 vs 
166 mg/dl, p <0.05) but a higher concentration of apo(a) (210 vs 87 U/l, p <0.05) 
than that in control group. 
As shown in Table 3-10, there was no much significant difference between 
the patient and control groups in LDL-P, LDL-C/P ratio, LDL particle size, and 
maximum propagation rate and diene accumulation (both p >0.05). However, CAD 
patients had a significant shorter oxidation lag time than that in control group ( 73.9 vs 
79.3 min, p <0.05). 
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Table 3-9. . Serum lipid-lipoprotein-apolipoprotein profile of CAD patients and 
controls v 
Parameters Patient Control p value 
Age 59 58 NS 
(years) (53-64) (55-63) 
TC 5.40 4.90 NS 
(mmol/1) (4.70-6.25) (4.15-6.45) 
TG 1.38 1.38 NS 
(mmol/1) (1.08-1.77) (1.07-1.67) 
LDL-C 2.65 2.65 NS 
(mmol/1) (2.29-3.26) (2.40-3.51) 
HDL-C 1.16 1.19 NS 
(mmol/1) (0.89-1.26) (1.05-1.48) 
Apo-AI 122 166 <0.05* 
(mg/dl) (117-143) (125-173) 
Apo-B 102 114 NS 
(mg/dl) (97-114) (86-127) 
Apo(a) 210 87 <0.05* 
(U/l) (129-259) (65-151) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference (n=15) 
NS : no significant difference 
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Table 3-10. Characterization of isolated plasma LDL in CAD patients and 
controls 
Parameters Patients Controls p value 
LDL-C 2.65 2.65 NS 
(mmol/1) (2.29-3.26) (2.40-3.51) 
LDL-P 542 563 NS 
(mg/1) (467-689) (474-786) 
LDL-C/P 1.85 1.78 NS 
(1.75-2.05) (1.68-1.99) 
LDL Oxidizability 
Lag Time 73.9 79.3 <0.05* 
(min.) (70.6-77.6) (73.6-81.5) 
Max. Propagation Rate 2.89 2.98 NS 
(xl0"6 mol diene formed / (2.60-3.14) (2.62-3.40) 
min/mmol LDL-C) 
Max. Diene Formed 1.57 1.55 NS 
(xio-4 mol/mmol LDL-C) (1.48-1.60) (1.48-1.65) 
LDL Particle Size 26.92 26.24 NS 
(nm) (25.47-27.36) (25.91-26.67) 
Data are presented as Median (Interquartile Range) 
* indicates significant difference (n=15) 






4.1 Patients and Controls 
Patients in this study had all been recruited from the various specialist outpatient 
clinics at the Prince of Wales Hospital. Informed consent was obtained from all of 
them for participation in the study. They were advised to remain on their diets and 
medications during the whole study period. Vitamin E supplement was discouraged 
since it would affect the lag time in the LDL oxidation experiment (56,99). Of the 
fifteen hypertriglyceridaemic subjects (group II), four subjects were excluded from 
patient-control analysis because they also suffered diabetes millitus that would 
otherwise overlap with NIDDM group (group I) for the interpretation. CAD subjects in 
the study were screened from about 170 CAD patients recruited from the clinics. 
However, the majority of them also concurrently suffered from other metabolic 
diseases. In order to investigate the unique features of cardiovascular disease, others 
than abnormalities contributed by known diseases (diabetes millitus, liver, thyroid and 
other diseases), hypertension, or hypolipidaemic drug, on the intrinsic properties of 
LDL particle size and oxidizability, patients suffered from those metabolic diseases 
were excluded from the study. As a result, only fifteen CAD subjects were left to take 
part in the study. 
Plasma total cholesterol concentration of 5.2 mmol/1 is commonly regarded as 
the cut-off value for normocholesterolaemia in normolipidaemia. However, we failed 
to screen out sufficient number of age and sex matched control subjects with TC < 5.2 
mmol/1 from about 150 control subjects recruited. Most of them had TC concentrations 
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from 5.4 mmol/1 to 5.9 mmol/1 (data not shown). As a result, the cut-off "normal" 
value for TC in this study was set at 5.5 mmol/1 to recruit more control subjects suitable 
for the study. The cut-off value of 5.5 mmol/1 was also adopted in some recent lipid-
lowering trials for the treatment of CVD patients (88). 
4.2 Ultracentrifugation of LDL Fractions 
The use of short-run ultracentrifugation (110,00 rpm; 140 minutes) and PD10 
desalting column in the study greatly reduced the time needed to isolate the plasma 
LDL fraction. The total processing time for the isolation of LDL fraction including 
ultracentrifugation, tube-slicing, desalting and cholesterol standardization was only 
about two and a half hour rather than more than 24 hours in those traditional isolation 
methods involving long-run ultracentrifugation and overnight dialysis (52,100). This 
should have minimized in vitro LDL oxidation prior to performance of the 
oxidizability studies. 
Standardized amounts of either cholesterol or protein may be used in the 
oxidation studies (95,101). However, the standardization of cholesterol concentration 
to 0.15 mmol/1 was adopted in the study as described by Chait (66) that lipids rather 
than proteins are the primary substrate to be oxidized initially in LDL particles. Such 
cholesterol standardization also allowed the investigation of other factors on LDL 
oxidizability rather than LDL-C concentration. 
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LDL-C measured by the ultracentrifUgation method in this study correlated 
reasonably well with that calculated by the Friedewald formula. However, the LDL-C 
values obtained in the ultracentrifuged samples tended to be lower than those estimated 
by the Friedewald calculation. The reasons for the negative bias are not understood. It 
is possible that the recovery of LDL-C by using this method was not fully complete or, 
less likely, the application of the Friedewald formula was not so appropriate for these 
samples. Although not performed in this study, it is advisable to validate this 
ultracentrifugation method by comparising the results with those by the Friedewald 
formula and by immunoseparation as described by Vrga (102). Nevertheless, the 
possible incomplete recovery of LDL-C would not affect the qualitative measurements 
of LDL oxidizability and particle size. The inter-assay CV of LDL-C was 2.9 % 
indicating a good reproducibility by using this ultracentrifugation method. All LDL-C 
reported in this study was obtained by the ultracentrifugation method rather than by the 
Friedewald calculation since most of samples in this study had TG concentration 
greater than 4.5 mmol/1 that the Friedewald formula is not valid in this condition. 
4.3 In Vitro LDL Oxidizability 
The kinetic profile of LDL oxidation was typical as shown in Fig. 1-7. The 
indexes of lag time, maximum propagation rate and diene accumulation were calculated 
by using a semi-programmed method described in Appendix n. The traditional manual 
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method to define these indexes is subjected to some drawing variations between each 
profile. The setting up of this programmed method allowed a standardized 
measurement for each oxidation profile throughout the study. 
From these three oxidative indexes, the lag time and maximum diene 
accumulation are of particular interest to be investigated and discussed in this study. 
The lag time is the most relevant and common parameter to define the susceptibility of 
LDL to oxidation reported by others using continuous diene measurement. It can 
reflect the extent of the resistance to oxidation. The maximum diene accumulation was 
itself not only an index of LDL oxidizability, but also to reflect the amount of 
unsaturated fatty acids incorporated into LDL particles which is one of critical factors 
to affect the resistance to oxidation (i.e. lag time). The change of this parameter might 
provide the essential information on the possible modification of fatty acid metabolism 
by those hypolipidaemic drugs, such as bezafibrate. 
The electrophoretic pattern of LDL fraction in agrose gels (Fig. 3-4) provided 
the information on the change of surface charge of LDL-apo B particles during in vitro 
LDL oxidation. LDL normally has a net negative charge and would migrate towards 
the anode. The predominance of lipid oxidation rather than protein oxidation in the 
early stage of Cu2+ mediated LDL oxidation did not disturb the surface charge of LDL 
particle which was indicated by the low mobility of LDL fraction in the first two hours 
(0 hour and 2 hour). Upon oxidation, LDL acquires a greater net negative charge, due 
to the neutralization of the positive charges of the lysyl residues of apo B as those 
oxidative products, such as aldehydes, bind to these (54). This subsequent increase in 
surface negative charge pulled the particle faster towards the anode as observed in 
subsequent incubation hours (4 hour and 24 hour). This kind of measurement can 
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provide a general information to monitor the progress of LDL oxidation. Unlike the 
diene measurement, this measurement is not continuous and the number of data 
obtained in each run is limited. 
4.4 Associations of TG，LDL Oxidizability and Particle Size 
The presence of the inter-correlation of plasma TG concentration, LDL 
oxidizability and particle size were reported by others (53,62,68,103). Such attempts 
were made to correlate these parameters in this study. The correlation result agreed 
with others (74,103) that plasma TG concentration significantly correlated with LDL 
particle size (r= -0.593，p <0.001) and seemed to be an important determinant 
governing LDL particle size even after statistically controlling other factors. 
Hypertriglyceridaemia is usually resulted in the formation of the smaller and denser 
LDL particles which are more atherogenic. This correlation may support the argument 
that hypertriglyceridaemia is one of factors to account for the increased risk of CVD. 
The triglycerides-lowering effect of some hypolipidaemic drugs, such as lovastatin and 
bezafibrate, may be therefore beneficial in reducing CVD risk. 
The negative correlation of oxidation lag time and maximum diene 
accumulation (r=-0.4754, p <0.001) reflects that the amount of unsaturated fatty acid 
present in LDL particle determines its susceptibility to oxidation. The increased supply 
of unsaturated fatty acid in LDL particles renders themselves more susceptible to 
oxidation. 
The positive correlation of LDL particle size and lag time (r=0.3298, p <0.001) 
indicates that the susceptibility of LDL oxidation increases with decrease in particle 
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size. The finding also demonstrates that smaller LDL particles (< 25.5 nm) are more 
susceptible to oxidation in term of shorter lag time and higher maximum diene 
accumulation than larger ones.. However, such correlation was lost after controlling 
for other factors (LDL-C, TC, TG and maximum diene accumulation) implying that this 
observed correlation might be caused indirectly by other factors, such as TG or diene 
concentrations. 
4.5 LDL Sizing 
The previously popular Pharmacia 2-16 % gradient gel was no longer available 
in the market. The 3-13% native PAGE gel from Gradipore Ltd (Australia) is one of 
two newly marketed gels for LDL sizing. All samples in this study were run by the 
same lot of product, thereby minimizing variations from different lots of gels. The 
inter-assay CV of a control sample was 1.8 % indicating excellent reproducibility. The 
use of 32 nm latex bead marker in this study was also different from the traditional uses 
of 38 nm or 28 nm latex beads (72,74). It was because the 38 nm latex beads were too 
large to migrate into the 3-13 % gel whereas the use of 28 nm latex beads as calibrator 
did not give a good linearity for the standard curve. The standard curve from these 
three markers (32 nm latex beads, thyroglobulin and ferritin) was excellently 
linearity with r >0.99. 
The Austin classification of LDL phenotypes A and B (26,78) has not been 
made in the study. That classification was based on the measurement of particle size at 
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a cut-off diameter of 25.5 nm using Pharmacia 2-16 % gel and the observation of the 
skewness of the band pattern. There was no comparison already reported at present to 
correlate the quantitative variations between gels from these two manufacturers, 
therefore it was not advisable to adhere to this cut-off value to identify LDL phenotype 
in this study. The lack of experience in the identification of the skewness of the band 
pattern is also a weakness in identifying the phenotype. Moreover, this dichotomous 
classification of LDL phenotype may not be a sensitive marker to investigate the mild 
differences between patients and controls, and drug before vs after treatment. For 
example, the drug medication may induce a change of LDL particle size without 
affecting the expression of the phenotype. 
4.6 Comparison of Patients and Controls in Lipid-Lipoprotein-
Apolipoprotein Profile 
As shown in Tables 3-1 and 3-5, NIDDM and hypertriglyceridaemic patients 
(Groups I and II) also exhibited typical lipid abnormalities with high plasma TC, TG 
and apo B concentrations, low HDL-C but relatively normal LDL-C concentration. The 
quantification of LDL-apo B rather than LDL-C is also important since it reflects the 
number of atherogenic LDL particle as each LDL particle carries one molecule of apo B 
(104). The effort had also been made to quantify LDL-apo B concentration but 
unsuccessful. Most of the values obtained was lower than 35 mg/dl which is the 
detection limit defaulted by Beckman Array 360 system (data not reported in the study). 
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It may be a technical fault that potassium bromide used in the ultracentrifugation 
interfered with the immunoprecipitin reaction of anti- apo B antibodies and apo B 
molecules as suggested by the consultant from Beckman Instruments (personal 
communication). It may also imply that there was a high concentration of apo B 
accumulated in VLDL particles or its remnants fractions. Our finding suggested that 
there was an accumulating VLDL particles and its remnants in the circulation since 
each VLDL particle or VLDL remnant also carries one molecule of apo B. The over-
secretion of VLDL remnants might account for the accumulation (30,105). The plasma 
lipid-lipoprotein-apolipoprotein profile (Table 3-9) in CAD patients did not different so 
much from the control group. The exclusion of those patients with hypolipidaemic 
drugs in the study implied that those remaining patients should not have abnormal lipid 
and lipoprotein profiles. 
Enhanced susceptibility to oxidation of LDL in both NIDDM, 
hypertriglyceridaemic and CAD patients (groups I, II and HI) was found and shown in 
Tables 3-2, 3-7 and 3-10 in term of shorter lag time in the LDL oxidation experiment, 
although the statistical analysis revealed differences only in the NIDDM and CAD 
groups. Higher contents of unsaturated fatty acids in LDL particles, reflected by higher 
maximum diene accumulation, in NIDDM and hypertriglyceridaemic groups (groups I 
and II) might promote the susceptibility to oxidation which had been already discussed 
before and reported by others (53,106,107). The pre-existence of high oxidative stress 
had been reported by others (108,109,110,111) that might render LDL more 
susceptibility to oxidation in NIDDM and CAD patients. The results in this study 
agreed with others (112,113,114,115) that DM patients had an enhanced susceptibility 
to LDL oxidation. Other reports have shown that hyperglycemia of diabetes millitus 
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may result in qualitative changes of LDL particles, such as glycation, oxidation, and 
combined glycation and oxidation. These structural changes result in the formation of 
some pre-formed lipid peroxidation products and oxygen free radicals in vivo, thereby 
rendering LDL particles more susceptible to subsequent oxidation in vitro (30,112,116). 
The enhanced susceptibility of LDL to oxidation is still controversial in CAD 
patients (117,118,119,120). The shorter lag time in CAD patients demonstrated in this 
study could not be explained by those risk lipid profiles since most of these lipid 
parameters (Tables 3-9 and 3-10) were not different from the control group. Although 
not measured in this study, other factors, such as high content of lipid peroxides and 
low content of antioxidant defense, have been already reported in CAD patients 
(111,121). It might possibly reflect the condition of an increased oxidative stress in 
CAD patients, thereby accounting for the increased susceptibility to in vitro LDL 
oxidation in those normolipidaemic CAD subjects. 
The failure to reveal any significant difference in lag time between 
hypertriglyceridaemic patients (group II) and the control group is in disagreement with 
other study (53) that dyslipidaemia is a critical factor to govern the susceptibility of 
LDL to oxidation. However, Leonhardt also failed to demonstrate the significant 
difference on the lag time in hyperlipidaemic subjects compared to controls (101). All 
oxidation measurements in Leonhardt and our groups were performed at a constant 
cholesterol concentration rather than protein concentration, however such relationship 
between LDL-C and lag time is not yet clear. The small sample size (n=ll) was also 
likely to limit the power to differentiate the statistical difference even though the value 
of lag time was greater in controls group. 
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The smaller LDL particle size found in NIDDM and hypertriglyceridaemic 
patients (groups II and II) is consistent with other studies (80,122,123,124). As 
discussed before, hypertriglyceridaemia is reported to be the most prominent factor 
regulating the size of LDL particles (81,125,126,127,128). 
Although our results disagree with others (64,65), the failure to show the 
significant difference in the LDL particle size between CAD and control subjects was 
not unexpected since the lipid and lipoproteins, especially plasma TG concentration, 
did not differ much between these two groups. 
The above findings illustrate the fact that dyslipidaetnic subjects are at high risk 
of developing CAD not only because of the quantitative abnormalities in lipid 
parameters, but also the qualitative changes of LDL particles in term of oxidizability 
and particle size. The modifications of these quantitative and qualitative parameters by 
drug treatment or vitamin E supplement are already found to be effective in reducing 
the prevalence of CAD (8,9,129,130). 
The effects of the medication of oral hypoglycemic and anti-hypertensive agents 
in NIDDM and hypertriglyceridaemic patients (groups I and H) on the LDL 
oxidizability and particle size are not definitely clear. However, the enhanced 
resistance to the susceptibility of LDL to oxidation were reported in some studies 
(131,132,133,134) concerning the use of either hypoglycemic or anti-hypertensive 
agents. Therefore they at least might not account for the shorter lag time in those 
patients (groups I and II) demonstrated in this study. 
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！“ 4.7 The Effect of Lovastatin and Acipimox on NIDDM Patients 
The observed reduction in plasma TC, TG, LDL-C, LDL-P and apo B together 
with the increase in HDL-C and apo A after 12-week lovastatin treatment are in 
accordance with previous reports on HMG CoA reductase inhibitors (9,89,135). Only a 
few studies on the effects of lovastatin on LDL particle size and oxidizability have been 
reported so far. The present findings demonstrated that lovastatin can not only increase 
the particle size but also retard the susceptibility of LDL to oxidation. The concurrent 
reduction of TG concentration by lovastatin treatment is likely to account for the 
change of LDL particle size as described before that the distribution of LDL 
subfractions paradoxically is inversely related with TG concentration. For in vitro LDL 
oxidizability study, similar treatments with other HMG CoA reductase inhibitors in 
other studies (135,136) still did not reveal a consistent result in LDL oxidizability. The 
underlying cause of the drug-induced change in oxidative susceptibility is currently 
undefined. However, smaller LDL particles are already reported to have an enhanced 
oxidative susceptibility. The increase in LDL particle size after lovastatin treatment 
observed in the study might be one of the reasons for the increased resistance to LDL 
oxidation. Aviram et al also demonstrates the antioxidant properties of lovastatin in 
vivo and in vitro experiment causing an increase in the resistance of LDL to oxidation 
(137). The changes of other intrinsic factors during drug treatment, such as free 
cholesterol (128,138) and antioxidant concentrations in LDL particles (139)，have been 
reported previously, which might also affect the oxidative behaviour (53), however 
they were not analy zed in this study. 
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One of the advantages for the use of the combined treatment in dyslipidaemic 
patients is to achieve a better improvement in lipid abnormalities. The distinct 
improvement of the combination treatment of lovastatin and acipimox in this study was 
to enhance the additional reduction of TG concentration and the increase in HDL-C 
concentrations, although the improvement was significant only in HDL-C (p <0.05). 
This combined treatment seems to be beneficial for those patients with severe 
hypertriglyceridaemia with low level of HDL-C. 
The removal of lovastatin from the combined therapy provided a wash-out 
period for the residual effect of lovastatin, thereby revealing the unique effect of 
acipimox on the lipid and lipoprotein profiles (WkO vs Wk36). The potent TG-
lowering and HDL-C raising effects of acipimox were demonstrated by a reduction 
of TG concentration (-17%) and an increase in HDL-C (+14%) when compared to the 
baseline. The rebound of TC and LDL-C concentrations (Table 3-3) almost to the 
baseline level revealed the minimal effect of acipimox on LDL-C metabolism as 
reported by Dean (140). 
The glycaemic control (i.e. blood glucose and HbAlc) remains unchanged 
during the whole period of drug medication is in agreement with others that the drug do 
not unfavourably affect glycaemic control (141,142,). 
Our findings also demonstrated a redistribution of LDL particle to a larger size 
by acipimox treatment which is consistent with others (143,144,145). Several potential 
mechanisms may have contributed to the changes that occur in LDL particles. The main 
role of hepatic lipase (HLP) seems to convert larger TG-rich lipoproteins, such as 
VLDL and IDL, to LDL and also between larger LDL to smaller LDL species. The 
inhibitory effect of HLP by acipimox slows the interconversions between LDL species, 
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resulting in the predominance of larger and more buoyant LDL particles. Second, the 
reduction of TG concentration by acipimox limits the supply of TG into LDL. The latter 
would remain rich in CE and hence be less susceptible to lipolysis (via HLP), thereby 
increasing its particle size and buoyancy. Third, the predominance of larger VLDL 
particles are usually accompanied by small, dense LDL particle and vice versa 
paradoxically (146). Therefore, the reduced TG concentration by acipimox might 
generate a decrease in the size of VLDL particles synthesized, thereby producing larger 
LDL particles (127). 
There was no much data reported on the effect of acipimox or other nicotinic 
derivatives on LDL oxidative susceptibility. Our results demonstrated that acipimox 
also seems to increase the resistance of LDL to oxidation. This phenomenon might 
also be resulted from the shift of LDL particles to larger sizes rendering them less 
susceptible to oxidation as discussed before. The concentration of unsaturated fatty 
acids in LDL particles is one of the factors governing the susceptibility to oxidation. 
Acipimox is known to inhibit the release and delivery of FFA into the liver (147,148). 
The non-significant decrease in maximum diene accumulation after acipimox found in 
the study (Table 3-4), might reflect a reduction of FFA acid incorporated in LDL 
particles, hence be less susceptible to oxidation. 
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4.8 The Effect of Bezafibrate on Hypertriglyceridaemic Patients 
The stimulation of LPL activity by bezafibrate is expected to account for the 
significant reduction of plasma TG after bezafibrate treatment (p <0.0001). The results 
here support that the drug has a potent triglycerides-lowering effect. The mild increase 
of HDL-C follows the observation that changes in TG level are usually accompanied by 
reciprocal changes in HDL-C (30)， although the mechanism is still not well 
understood. The increase of LPL activity may result in the release of essential 
components from TG-rich VLDL for more HDL particles synthesis. The retardation of 
CETP-mediated transfer of CE out of HDL in exchange for TG into VLDL may also 
result in the increase of HDL-C in the circulation (149). The rise of LDL-C after 
bezafibrate treatment was a little surprise. However, Grundy (150) had pointed out 
that the effect of fibrate therapy upon LDL-C concentrations depends upon the patients' 
overall lipid and lipoprotein status. Elevated LDL-C concentration has been already 
reported in some hypertriglyceridaemic patients with gemfibrozil therapy (137,151), 
although the underlying mechanism is undefined. The fibrate-induced balance between 
the promotion of the conversion of VLDL to LDL, the increase activity of LDL 
receptor pathway, and the inhibition of intracellular cholesterol synthesis seem to 
determine the ultimate LDL-C level in the circulation (90). In this study, the reduction 
of LDL-C without affecting total cholesterol concentration after bezafibrate treatment 
indirectly reflected that there was a significant decrease in VLDL-C (Table 3-6). It 
concurs with the mechanism of action of fibrates that the latter appears to stimulate the 
LPL for lipolytic action on VLDL particles and to reduce the secretion of VLDL 
particles from the liver (90). 
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Our results are also in agreement with previous reports on fibrates (137,152) 
that bezafibrate has an effect on the distribution of LDL species as the LDL particle size 
was increased after treatment. This change is seen to be apparently secondary to 
reduced concentrations of TG-rich lipoproteins as mentioned before. The significant 
increase in LDL C/P ratio (p <0.01) found in this study is consistent with the shift to a 
larger and more buoyant LDL species. 
Only a few studies have reported the effect of bezafibrate on LDL oxidizability 
(138,153,154). Our results demonstrated that bezafibrate has an anti-oxidant potential 
on LDL oxidation resulting an increase in lag time, and a decrease in maximum 
propagation rate and diene accumulation (Table 3-8). It may be explained as similar as 
in acipimox treatment that bezafibrate treatment does not only increase the LDL 
particle size but also limit the availability of FFA for triglycerides synthesis (90). An 
increase of free cholesterol in LDL particles with fibrate therapy had also been reported 






An elevated plasma concentration of low density lipoprotein cholesterol(LDL-
C) is an established risk factor for coronary artery disease (CAD). Many clinical 
intervention studies have demonstrated the therapeutic value of lowering LDL-C level 
in reducing the risk of CAD. However, recent studies have shown the close 
association of hypertriglyceridaemia and low high density lipoprotein cholesterol 
(HDL-C) levels with CAD. The intrinsic atherogenic properties of LDL particle size 
and oxidizability have also been linked with accelerated atherosclerosis. These lipid-
lipoprotein risk factors are collectively suggested to be one of causative factors 
contributing to the high prevalent rate of CAD, especially in non-insulin dependent 
diabetes millitus (NIDDM) patients. The implementation of lipid-lowering program 
seems to be the most cost-effective strategy in the reduction of the prevalence of CAD 
in dyslipidaemic patients. 
The unique feature of this project was not only to investigate the effectiveness 
of some commonly used hypolipidaemic drugs on quantitative changes in patients' 
plasma lipid profile, but also to establish methods for the study of the characteristics of 
LDL particle size and oxidizability in various disease status and their possible 
qualitative changes when subjected to drug therapy. 
Elevated TC and TG and reduced HDL-C concentrations were common 
characteristics for dyslipidaemic patients including NIDDM patients. Once again our 
findings showed the possibility of the accumulation of VLDL or its remnant particles in 
these patients since their LDL-C concentrations were not elevated. The over-secretion 
of these VLDL particles or their impaired lipolysis may account for these plasma lipid-
lipoprotein abnormalities. 
Our results also demonstrated the presence of smaller and denser LDL particles 
in these dyslipidaemic patients. Hypertriglyceridaemia was likely to be a contributing 
factor for this abnormality as TG level was found negative correlated with LDL particle 
size. The relative shorter lag time of the in vitro LDL oxidizability experiment in both 
groups of dyslipidaemic patients (although not significant in the group of 
hypertriglyceridaemic patients) demonstrated that their LDL particles were more 
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susceptible to oxidation. Both these two intrinsic risk factors further predisposed these 
patients to a higher risk of CAD. Within these dyslipidaemic patients, the findings 
pointed out the possibility of the presence of other non-lipid risk factors, such as 
increased oxidative stress and hyperglyacemia, may contribute to the enhanced 
susceptibility to LDL oxidation in NIDDM. 
Our results support that lovastatin is definitely a potent drug to reduce LDL-C 
and TG concentrations with a mild increase in HDL-C whereas acipimox is an effective 
drug in reducing TG with a mild increase in HDL-C but not effective on reducing LDL-
C. The combined therapy of these two drugs not only further enhances TG-lowering 
but also increases HDL-C significantly. Bezafibrate is no doubt an effective drug to 
reduce TG concentration. However, the concurrent increase in LDL-C, especially in 
severe hypertriglyceridaemic subjects, needed to be considered in the choice of this 
drug. The combination with other drugs, such as statins, may be the alternate choice in 
the treatment of combined hyperlipidaemic patients. 
All of these three drugs demonstrated their favourable effects on increasing 
LDL particle size and reducing its susceptibility to oxidation. The mechanisms of these 
modification are not clearly defined but the changes of LDL particle size, cholesterol-
protein ratio and fatty acid contents may contribute to the qualitative improvement of 
these intrinsic properties. 
In summary, the above findings suggest that the intrinsic properties of LDL 
particle size and oxidizability, other than those well-established quantitative lipid-
lipoprotein-apolipoprotein risk factors, may also play a role in the development of 
atherosclerosis, thus contributing to a high prevalence of coronary disease in 
dyslipidaemic subjects. The use of singly or in combination, lovastatin, acipimox and 
bezafibrate, will improve not only the quantity of lipid and lipoprotein profiles but also 
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APPENDIX III . 
а. The parameter listing of LDL cholesterol measurement in Cobas 
Bio analyser 
L UNITS MMOL/L 
2. CALCULATION FACTORS 0 
3. STANDARD 1CONC 2.07/1.04* 
4. STANDARD 2 CONC 4.15/2.07* 
5. STANDARD 3 CONC 0 
б. LIMIT 4.15 
7. TEMPERATURE[DEG.C] 37.0 
8. TYPE OF ANALYSIS 5 
9. WAVELENGTH[NM] 520 
10. SAMPLE VOLUME[UL] 20 
11. DILUENT VOLUME[UL] 60 
12. REAGENT VOLUME[UL] 300 
13. INCUBATION TIME[SEC] 0 
14. START REAGENT VOLUME[UL] 0 
15. TIME OF FIRST READING[SEC] 5.0 
16. TIME INTERVAL[SEC] 300 
17. NUMBER OF READINGS 02 
18 BLANKING MODE 1 
19. PRINTOUT MODE 1 
* for low concentration of LDL-C 
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APPENDIX III . 
b. The parameter listing of LDL protein measurement in Cobas Bio 
analyser 
L UNITS UG/ML 
2. CALCULATION FACTORS 0 
3. STANDARD 1CONC 25 
4. STANDARD 2 CONC 50 
5 • STANDARD 3 CONC 100 
6. LIMIT 100 
7. TEMPERATURE[DEG.C] 25.0 
8. TYPE OF ANALYSIS 1 
9. WAVELENGTH[NM] 595 
10. SAMPLE VOLUME[UL] 10 
11. DILUENT VOLUME[UL] 00 
12. REAGENT VOLUME[UL] 290 
13. INCUBATION TIME[SEC] 10 
14. START REAGENT VOLUME[UL] 0 
15. TIME OF FIRST READING[SEC] 0.5 
16. TIME INTERVAL[SEC] 120 
17. NUMBER OF READINGS 02 
18 BLANKING MODE 1 
19. PRINTOUT MODE 1 
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APPENDIX III . 
The calculation of lag time, maximum propragation rate and diene 
accumulation in the LDL oxidation experiment 
Absorbance at 234 nm is taken every 2 minutes by Beckman DU650 spectrophotometer 
and the data is imported into the spreadsheet program EXCEL. The folllowing 
parameters are computed : 
(a) Lag time : calculated as the time intercept between the line 
of maximum slope of the propagation phase and the 
absorbance baseline. 
Slope of absorbance change is first calculated by dividing the absorbance 
change between each measurable point by time interval( i.e. 2 minutes). 
y is defined as absorbance at 234 nm 
x is defined as time interval point 
Slope(Sn) = ( y n - yn-i)/ 2 at particular interval point (yn, xn) (1) 
At a particular interval point (y max, x max) with maximum slope value (Smax). 
The line of maximum slope of the propagation phase is derived by using point-
slope method. 
i.e. (y-ymax)/(x-Xmax) = S max 
y = S max * (x-xmax) + Ymax � 
The absorbance bassline is defined as the average of the first five absorbance 
data. 
i.e. yo = (yi + y2 + Y3 + y4 + ys)/5 (2) 
By solving equations (1) and (2), the value of x is computed, which is the time 
intercept between these two lines and is equivalent to the oxidation lag time. 
Lag time = (yo -ymax + Smax * xmax)/ Smax 
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(b) Total absorbance change : calculated as the difference between the 
maximum absorbace obtained and the 
absorbance baseline (i.e. yo) 
By using Beer' law, A= abc A= absorbance 
a = Molar absorptivity (29500 1/mol/cm) 
b = light path (cm) 
c = diene concentration (mol/1) 
Maximum diene accumulated is defined as the maximum absorbance obtained 
divided by molar absorptivity and light path, and is calculated by the rearrangement 
of the equation. 
i.e. c = A/ab 
Maximum propagation rate is defined as the maximum change of absorbance divided 
by molar absorptivity, light path and time intervals (i.e. 2 minutes) 
i.e. c = A/2ab 
The values of maximum propagation rate and diene accumulation are finally reported 
after standardization of LDL-C concentration (i.e. 0.15 mmol/1). 
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APPENDIX III . 
a. The parameter settings for LKB 2202 ultrascan densitometer 
SCAN SPEED 30 
START POSITION 10 
END POSITION 80 
b. The parameter settings for HP integrator 
ZERO ~ ~ M 
ATT 2A 9 
CHTSP 6 
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